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ABSTRACT
 
The goal of this study was to isolate the impact of chorea on voluntary 
movements, in order to better assess the role of involuntary movement in motor 
disturbances observed in patients with Huntington's disease. Whole-body involuntary 
movements (WBIM) and voluntary motor acts were recorded simultaneously, using a 
magnetic tracker system, in fifteen choreic RD patients and fifteen healthy age-, gender­
matched control subjects. Participants were asked to perform two distinct tasks, a rapid 
altemating movement (RAM) task, yielding measures of bradykinesia and hypokinesia, 
and a manual-tracking (MT) task yielding a measure of chorea intrusion during accurate 
movements. 
Patients with RD had better RAM performance than healthy controls, this 
finding ruling out the presence of core bradykinesia in these patients. During the manual 
tracking task patients with RD showed deviations from the target that significantly 
hindered their ability to match target velocity. In addition, error in performance was 
correlated wi th the amplitude of whole-body chorea, illustrating the deleterious effect of 
chorea during accurate movements. These results clearly show that core bradykinesia is 
not a symptom of RD when chorea is predominant, but that chorea is the main cause of 
error in performance during accu rate movements. Accordingly, patients with RD would 
greatly benefit from therapeutic treatment aimed at reducing chorea while maintaining 
proper motor function. 
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RESUME 
Le but de cette étude était d'isoler l'impact de la chorée sur les mouvements 
volontaires, pour mieux évaluer le rôle des mouvements involontaires sur les 
perturbations motrices observées chez les patients ayant la maladie de Huntington. Les 
mouvements involontaires du corps ainsi que les actions motrices volontaires furent 
enregistrés simultanément, à l'aide d'un système de pistage magnétique, chez quinze 
patients choréiques ayant la maladie de Huntington ainsi que chez quinze sujets contrôle 
en bonne santé de même âge et sexe. Il a été demandé aux participants d'accomplir 
deux tâches distinctes; une de mouvements alternés rapides (RAM) qui permettra de 
quantifier l' hypokinésie et la bradykinésie, et une tâche de poursuite manuelle (MT) qui 
fournira une mesure quant à l'intrusion des chorées lors de mouvements précis. 
Les patients ayant la maladie de Huntington ont obtenu de meilleurs résultats 
comparativement aux sujets contrôles lors de la tâche RAM, démontrant ainsi l'absence 
de bradykinésie chez ces sujets. Lors de la tâche MT, les patients ayant la maladie de 
Huntington ont démontré une déviation par rapport à l'emplacement de la cible réduisant 
ainsi leur habileté à reproduire sa vitesse. De plus, une corrélation fût établie entre 
l'erreur au niveau des performances et l'amplitude des chorées du corps, illustrant l'effet 
néfaste des chorées lors de mouvements précis. Ces résultats démontrent clairement que 
la bradykinésie n'est pas un symptôme de la maladie de Huntington lorsque des chorées 
sont présentes, mais que les chorées sont la principale cause d'erreur de performance 
lors de mouvements précis. Donc, les patients atteints de la maladie de Huntington 
bénéficieraient grandement de traitements visant à réduire les chorées tout en maintenant 
une fonction motrice adéquate. 
Mot clefs Huntington, bradykinesia, chorée, quantification, Parkinson 
1. INTRODUCTION 
One in every 10,000 Canadians suffers from Huntington' s Disease (HD) 
(Huntington Society of Canada 2005) a statistic that places Canada at the high end of 
world prevalence rates, 4-10 pel' 100,000 (Qin et al. 2005; Reddy et al. 1999). HD is a 
genetically inherited neurodegenerative condition caused by the unstable expansion of 
the CAG tIinucleotide repeat (Myers 2004; Berardelli et al. 1999; Canals et al. 2004). 
The repeat results from a mutation of the gene that encodes the protein huntingtin, 
located on chromosome 4p16.3 (Myers 2004; Huntington's Disease Collaborative 
Research Group 1993). Huntingtin protein is thought to be necessary for developing and 
sustaining normal brain function (Menalled el al. 2002; Young 2003). lID is 
characterized by disordered voluntary and involuntary movement (Carella et al. 2003; 
Bilney et al. 2005; Berardelli et al. 1999; van Vugt et al. 2004), cognitive deficit and 
psychiatrie symploms (Gardien et al. 2004; Naarding et al. 2001; Young 2003). 
Although the genetic cause of the disease has been isolated, there are no existing 
therapies to delay or prevent onset (Bhidayasiri & Truong 2004), and treatment is aimed 
at the alleviation of symptoms (Bilney et al. 2003). 
The pathophysiology of HD is marked by a progression from hyperkinetic to 
hypokinetic movements in typical adult onset (Berardelli el al. 1999), although there is 
extensive variability in motor symptom expression. HD is the most common cause of 
chorea (Bhidayasiri & Truong 2004), the presence of which often decreases as disease 
progresses to later stages (Berardelli et al. 1999). There is evidence to suggest that 
chorea and other involuntary movements in HO negatively affect motor function,' 
specifically accuracy (Phillips et al. 1996; Bilney et al. 2003) and gait regulation (Bilney 
et al. 2005). The motor symptoms of Huntington's disease have been researched for 
many years but very [iule work has been dedicated to the specifie movement 
charactelistics of choreic patients. Due to the lack of therapeutic options currently 
available to effectively treat chorea in HO it is essential to establish a greater 
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understanding of this involuntary movement, its characteristics and the neural networks 
involved in its expression. 
The first general aim of this study is to quantify the mutual influence of chorea 
and voluntary movement in patients with adult onset Huntington's disease. 
Quantification of chorea during voluntary movement will enable a greater understanding 
of the mutual influence of chorea and voluntary movement, and ifs application to 
therapies aimed at improving performance of daily living activities and the maintenance 
of quality of life in choreic patients. 
Treatment of motor symptoms, specifically chorea, is not suggested unless the 
condition becomes debilitating, as therapies used have extensive negati ve side effects 
and may aggravate psychiatric symptoms (Bhidayasiri & Truong 2004). Adverse side­
effects associated with anti-choreic medication include parkinsonism, sedation, 
insomnia, depression, anxiety and akathesia (Bonelli et al 2004). It has been suggested 
that chorea may not be the only, or most influential source of motor disability in HO 
(Thompson et al. 1988). The coexistence of hyperkinetic and hypokinetic motor 
behaviour in patients with HO (Thompson et al. 1988; Joel 2001) makes it increasingly 
difficult to isolate the main source of error in movement, as weil as the effects of each 
condition on performance (Hanajima et al. 1999). The lack of data on un-medicated HO 
patients calls into question whether the hypokinetic features of movement, e.g 
bradykinesia, are a natural symptom of the disease or a condition brought on, or 
aggravated, by drug therapy. It is imperative to isolate and quantify the existence of 
hyperkinetic and hypokinetic characteristics in HO in order to determine which is the 
more influential source of disability. 
The second general aim of this study is to determine if bradykinesia co-exists 
with chorea in patients with adult-onset Huntington' s disease. Quantification of 
hyperkinetic and hypokinetic features of motor behaviour in patients will enable a. 
baseline understanding of motor symptoms in the disease and their interaction with one 
another during performance. This information will enable more accurate and efficient 
tailoring of drug therapy to alleviate negative motor symptoms without introducing any 
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new impairment such as those adverse side effects previously experienced with drug 
treatment. 
2. REVIEW OF LITERATURE 
The following review of literature will outline current information regarding the 
types, prevalence, progression, aetiology and pathophysiology of Huntington' s disease, 
with specifie focus on the motor behavior and abnormalities associated with this disease. 
This review is designed to establish a foundation of information regarding BD in order 
to form an understanding of those aspects of the condition that are widely accepted, 
controversial, or yet unknown. The rational of this study wi Il then be discussed based on 
these findings. 
2.1 Huntington's Disease (HD) 
The cardinal pathological feature of HD is loss of medium spiny neurons in the 
striatum (Backman & Farde 2001), specifically those with GABAergic projections to the 
external pallidum and SNr (Weeks et al. 1997; Reiner et al. 1988). Striatal degeneration 
in BD progresses along mediolateral and dorsoventral gradients affecting the 
dorsornedial caudate and dorsal putamen (Joel 2001; Quinn & Schrag 1998). Currently 
there is no known method to hait or reverse the striatal damage caused by BD. 
BD, occurring at a rate of 10 per 10,000 among Caucasian populations, with no 
gender preference (Bhidayasiri & Truong, 2004), has a mean age at onset of 32-42 years 
with a rnean disease duration of 15-17 years (Quinn et al. 1998). The condition is 
autosornal dominant and 90% of cases are inherited from the father (Quinn et al. 1998), 
offspring of an effected family member have a 50% chance of having inherited the fully 
penetrant mutated gene (Myers 2004; Bhidayasiri & Truong, 2004). Age of onset has 
been inversely correlated with CAG repeat length in BD (Saft et al. 2003; Reddy et al. 
1999; Young 2003), although repeat length accounts for only 50% of variance in age at 
onset (Albin et al. 1995). HD is associated with repeat instability (Ross et al. 1997) and 
genetic anticipation (Young 2003; Reddy et al. 1999). Instability in HD increases with 
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the transmission of longer repeats, paternal transmission can expand more then 1-2 
triplets in length (Ross et al. 1997; Mangiarini et al. 1997). Anticipation, increasing 
disease severity and decreasing age of onset, occurs most commonly through patemal 
transmission (Ross et al. 1997). Approximately 28% of cases are late onset, 50 years and 
older, and on[y 6% juvenile onset (Quinn & Schrag 1998). The Westphal variant, also 
known as the rigid akinetic type and clinically associated with early/juvenile onset is 
very rare and presents with seizures, action tremor, bradykinesia, eye movement 
abnormalities, cerebellar ataxia and dystonia (Magnet et al. 2004). Pathophysiologic 
characteristics of Westphal variant include atrophy of the direct striatal pathway to GPi, 
globus pallidus internus, and atrophy of enkephalin striatal projections to the GPe, 
globus pallidus externus (Albin et al. 1990; Magnet et al. 2004). Adult onset is the 
predominant form of HO, responsible for approximately 68% of cases (Quinn & Schrag 
1998). This form presents initially with motor 'clumsiness' due to abnormal voluntary 
movement, bradykinesia (Sanchez-Pernaute et al. 2000) and involuntary movemenl, 
such as motor tics and chorea (Ross et al. 1997). Predictive genetic testing is available 
for indi viduals with a family history of the condition (Evers-Kiebooms et al. 1998), 
testing predicts whether asymptomatic individuals will be affected by the condition later 
in life. 
Although the onset of Huntington' s disease has long been associated with the 
presentation of motor symptoms (Georgeou et al. 2003), recent research has shown that 
cognitive and emotional disturbances may pre date motor signs (Lawrence et al. 1998; 
Snowden et al. 2002). 
Stage or progression of HD is measured using c1inical scales such as the total 
functional capacity (TFC) scale and the Unified Huntington disease rating scale 
(UlIDRS) (Shoulson 1979; Huntington Disease Study Group 1996). The total functional 
capacity (TFC) scale is a standardized measure of capacity to participate in activities in 
the workplace and home, on a scale from 13 (normal) to 0 (severe disability). According 
to the TFC scale there are five stages of progression in adult-onset Huntington's disease 
(Shoulson 1979). Stages encompass a wide range of years from diagnosis due to the 
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variance in progression and expression of symptoms and degeneration in lID. The first 
stage encompasses diagnosis up to eight years into the disease, engagement in the 
individuals occupation is nonnal, ability to handle financial affairs and domestic 
responsibilities remains in-tact, as weil as full ability to perform activities of daily living 
independently. The second stage occurs 3-13 years from diagnosis, engagement in work 
and financial affairs is diminished but household responsibilities and daily activities can 
be completed independently. The third stage, occurring anywhere From 5-16 years from 
diagnosis, a1l activities are impaired and assistance is required, either home or 
institutional care. The fourth and fifth stage, 9-21 and 11-26 years from diagnosis, 
respectively, individuals are unable to function at work, handle financial affairs or 
manage domestic responsibilities and the inability to complete activities of daily life 
make full institutional care a necessity. For corresponding stages and TFC score values 
see Table 1. 
Table 1. Total Functional Capacity (TFC) scale. Adapted from Shoulson 1979. 
Disease Stage TFC Score Years since diagnosis 
Stage I 11-13 0-8 
Stage II 7-10 3-13 
Stage III 3-6 5-16 
Stage IV 1-2 9-21 
Stage V 0 11-26 
The UHDRS is the gold standard clinical tool for assessing the four domains of 
clinical capacity and performance in lID. The UHDRS assesses motor and cognitive 
function, behaviour abnormalities and overall functional capacity (Huntington Study 
Group 1996). The UHDRS has been found useful in tracking changes in the clinical 
features of lID over time and has excellent inter-rater reliability (Huntington Study 
Group 1996). The UHDRS provides a more specific quantification of capacity in the 
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four clinical domains of HD than the TFC and, therefore, will be used to score patients 
in this study. 
2.1.1 Aetiology 
Huntington's disease is attributed to a dynamic mutation in a single gene, IT15 
(Ross et al. 1997), also known as the huntingtin gene (Bertram 2005), involving a repeat 
expansion in the coding region that affects protei n structure (van Dellen et al. 2005). The 
product of this mutation is referred to as mutant htt. An increased number of CAG 
repeats, nucleic acids cystine, argnine and guanine, which code for the amino acid 
glutamine, in the HD gene on chromosome 4p 16.3 causes disease ex pression (Myers 
2004). CAG repeats occur normally 6-35 times, increased to 40-121 repeats in HD 
(Reddy et al. 1999; Myers 2004). There is an inverse correlation between repeat length 
and age at onset (Saft et al. 2003; Young 2003), patemal transmission is sensitive to 
allele expansion, and this instability of transmission contributes to the anticipation 
observed in HD and other repeat disorders (Ross et al. 1997). The normal function of 
huntingtin is unknown (Albin & Tagle 1995), but has been linked to the development 
and maintenance of normal brain function (Young 2003) and is thought to function 
primarily cytoplasmically in cytoskeletal function or vesicle recycling (Ross 2002). 
Huntingtin is also associated with organelles such as endoplasmic reticulum, the nucleus 
and golgi-complex (Cattaneo et al. 2005). The aetiology of Huntington's disease remains 
unknown, two main theories have surfaced in an attempt to explain the cause and course 
of neurodegeneration in this disease: confonnational toxicity through amyloid-like 
protofibril formation (aggregation or inclusion bodies) and altered gene expression 
(Valera et al. 2005). 
2.1.2 Aggregation 
The abnormally expanded mutant htt is c1eaved or truncated by the ubiquitin 
proteasome system (UPS) (Valera et al. 2005). The UPS performs a variety of cellular 
functions, most importantly the removal of abnormal or inconectly assembled proteins 
(Valera et al. 2005). This truncati<;>n results in the production of toxic polyglutamine 
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containing fragments that interact with other intracellular proteins, including 
components of the proteasome, aggregating in the cytoplasm and nucleus forming 
inclusion bodies (van Oellen et al. 2005). Protein-protein interaction is implicated in the 
neurodegenerative process of Huntington's disease (Sharpe & Ross 1996). It has been 
, 
suggested that glutamine repeats acts as polar zippers, joining proteins with an affinity 
for each other (Perutz et al. 1994). Repeat expansions may then acquire excessive 
affinities for each other or regulatory proteins when expanded in disease conditions 
(Sharpe & Ross 1996; Perutz et al. 1994), and this excessive affinity may account for the 
cascade of events leading to the formation of inclusion bodies. A hypothetical pathway 
for formation of inclusion bodies involves a cascade of binding reactions from soluble 
mutant htt monomers to oligomers which are linearly assembled into protofibrils which 
form fibrils which form filaments that together with other cellular proteins such as 
molecular chaperones, transcription factors, cytoskeletal proteins and components of the 
proteasome system, form inclusion bodies (Valera et al. 2005). The function of 
aggregation is controversial (Reddy et al. 1999). Evidence of protein aggregates in non­
neural tissue refutes their role in cell death (Hague et al. 2005); also preferential location 
of Huntington aggregates in striosomes in I-ID support a positive, possibly 
neuroprotective role in the disease (Menalled et al. 2002). Evidence has also been found 
to suggest a neuroprotective role of aggregation in a study examining wild type htt 
aggregation in vivo, results show wild type htt modulates neuronal sensitivity to 
apoptotic death due to N.MDA receptor mediated excitotoxicity (Leavitt et al. 2006; 
Cattaneo et al. 2005). 
2.1.3 Altered Gene Expression 
Altered gene expression, resulting from the mutation of the huntingtin gene, may 
result in deregulation of brain derived neurotrophic factor (BDNF) (Canals et al. 2004), 
altered endocytosis and vesicular transport, abnormalities of synaptic transmission, 
mitochondrial dysfunction (Schulz & BeaI 1994), the activation of apoptotic pathways 
and impairment of the UPS (Valera et al. 2005; van Oellen et al. 2005). BDNF protects 
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striatal neurons and is regulated by huntingtin through protein interactions (Canals et al. 
2004; Cattaneo et al. 2005). BDNF has been shown to regulate the age of onset and 
sevellty of motor dysfunction through protection of striatal enkephalinergic neurons in 
transgenic mice, suggesting that administration of exogenous BDNF may delay or hait 
disease progress (Canals et al. 2004; van Dellan et al. 2005). Wild type htt stimulates 
BDNF vesicular trafficking, and mutant htt inhibits it, as weil as interacting with 
huntingtin associated proteins to enhance vesicular transport intra-cellularly (Cattaneo et 
al. 2005). A disruption of this function would lead to reduced or abnormal protein 
trafficking, affecting endo and exo-cytosis at synaptic terminaIs (Cattaneo et al. 2005). 
Abnormalities of synaptic transmission can be due to the disruption in the expression of 
genes encoding synaptic and intra-neuronal signaling proteins, this could lead to the 
disruption of cortico-striatal networks, via the reduction of dendritic spines in medium 
spiny neurons of the striatum (van Dellan et al. 2005). Mitochondrial dysfunction is a 
leading mechanism implicated in the neural degeneration found in a number of diseases 
(Schulz & Beai 1994). In HO brain tissue there is an increased level of lactate and 
decreased mitochondrial respiratory chain function (Andreassen et al. 2001). Creatine 
administration has been found to improve this condition, as weIl as increasing survival 
and delaying motor symptom onset in HO mice (Andreassen et al. 2001). Markers of 
mitochondrial activity have been found to be reduced in transgenic HO mice, as weil as 
decreased oxidase activity in human HD brains (van Dellan et al. 2005) supporting a role 
for mitochondrial dysfunction in ceIl death, if not as a cause, at least as a contributing 
factor (Schulz & Beai 1994). Wild type huntingtin is neuroprotective, particularly due to 
the fact that it inhibits the formation of pro-apoptotic protein interactors. AIso, 
huntingtin can act as a substrate for a kinase, which acti vates pro-survival pathways 
(Cattaneo et al. 2005). Excitotoxicity, resulting from the prolonged acti vation of 
excitatory receptors (for example glutaminergic receptors in the basal ganglia), leads to 
cell damage and death (Doble 1999). Medium spiny neurons, those preferentially 
affected in HO, receive large amounts of glutaminergic input and their vulnerability to 
excitotoxicity may be increased by decreased glutamate uptake by glial cells in HD 
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(Shin et al. 2005). Cell death is a secondary issue in Huntington's disease: it is cell 
dysfunction that plays a more influential role in disease expression (van Dellen et al. 
2005). Impairment of the ubiquitin proteasome system (UPS) is easily related to 
formation of aggregates and inclusion bodies, due to the impaired ability of the UPS to 
remove abnormal or misformed proteins, as weil as impaired removal of regulatory 
proteins leading to cellular deregulation and cell death (Valera et al. 2005). These two 
mechanisms and their associated consequences are supportable hypotheses in the search 
to understand the aetiology of Huntington's disease, although they are still shrouded in 
controversy due to discovery of incongruent findings in human and animal models 
(Valera et al. 2005). 
2.2 Basal Ganglia Pathophysiology 
Models of the basal ganglia have been used to map a number of clinical findings 
in movement disorders such as Parkinson's disease and Huntington's disease. In order to 
understand the progression and expression of Huntington's disease, as weil as the unique 
movement characteristics of chorea, it is important to first understand the role of the 
basal ganglia in movement. 
The basal ganglia (BG) is comprised of the striatum (caudate and putamen), the 
globus pal1idus (internai and external segments), the subthalamic nucleus and the 
substantia nigra (pars compacta and pars reticulata). The thalamus is closely linked to 
the basal ganglia, although not considered a part of the structure, it acts as a relay nuclei 
in many basal ganglia loops. The BG nuclei facilitate transport of sensorimotor, limbic 
and cogniti ve information through fi ve pathways organized in parallel loops: the motor, 
oculomotor, limbic and two prefrontalloops (Alexander et al. 1986). When investigating 
movement disorders, specifically HD, the motor loop is of primary concern, particularly 
because of its raie in the planning and execution of movement. The motor loop begins in 
the primary sensory and motor cortical areas, as weil as the supplementary and premotor 
areas. These areas contain projections to the putamen, the input nuclei of the BG located 
in the striatum (Alexander et al. 1986). From the putamen the loop continues to the 
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output nuclei, internai segment of the globus pallidus and substantia nigra pars reticulata 
which project to the ventral lateral (VL) and anterior thalamus (VA) (Wichmann & 
DeLong 1996). The thalamus then completes the motor loop with projection back to the 
cortex that facilitates information transfer to the brainstem and spinal cord (Yelnik 2002; 
Alexander et al. 1986). (Fig 1). 
Corte x 
---I~~ Dopamine 
---.....1&---...............---. Excitatory/inh ibitory
 
---l''~ ExcitatorySTN Glutamate 
...._-_.. ---I~~ Inhibitory 
GABA 
Figure 1. Model of the BG. This figure outlines the CUITent model of the Basal Oanglia. 
The motor loop begins in the cortex and projects to the striatum, the major input nuclei 
of the BO. The OPi and SNr are the major output nuclei of the BO, and the thalamus 
serves as a relay nuclei back to the cortex. (Adapted from Albin et al. 1989) 
2.2.1 Direct and Indirect Pathways 
The popular view of the BG mator loop is that of two opposmg parallel 
pathways, the direct and indirect pathways, and that an increase or decrease in 
movement is based on manipulation of GPi output (Mink 1996). The direct pathway is 
activated by dopamine at the Dl receptars in the striatum that channels GABA, an 
inhibitory neurotransmitter, along projections to the GPi and SNr. The GPi has 
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inhibitory projections to the thalamus, the disinhibition of the thalamus in the direct 
pathway increases excitatory glutamatergic activity to the motor cortex (Silkis 2002; 
Wichmann & DeLong 1996). The indirect pathway is inhibited by dopamine at the D2 
receptors of the striatum that also channel GABA, via connections to the GPe, which 
projects to the STN (Mink 1996; Silkis 2002; Wichmann & DeLong 1996). The 
subthalamic nucleus (STN) then projects to the GPi via excitatory glutamatergic 
connections. These excitatory connections reduce inhibition of GPi, increasing 
inhibitory GABA released to thalamus, thus decreasing excitatory glutamatergic 
projections to the motor cortex (Mink 1996). The direct pathway facilitates desired 
movements through increased thalamocortical activity, while the indirect pathway 
inhibits undesired movements by decreasing thalamocortical activity. (Fig. 2) 
a) Direct pathway b) Indirect pathway 
Thalamus 
.....--+....... 1 GPe 1
 
Dopamine Dopamine 
excitatory inhibitory 
Excitatory --.ExcitatorySTNGlutamate Glutamate 
Inhibitory -----.. Inhibitory 
GABA GABA 
Figure 2. Direct and Indirect Pathways. a)The direct pathway begins in the striatum at 
the site of the DI receptors, inhibiting the GPi/SNr via GABAergic projections, the OPi 
have GABAergic projections to the thalamus. b)The indirect pathway begins at the D2 
receptors in the striatum and have OABAergic projections to the OPe which has 
GABAergic projections to the STN, the STN has glutamenergic projections to the GPi. 
Excitation of the GPi/SNr by the STN activates GABAergic projections to the thalamus. 
(Adapted from Albin et al. 1989) 
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2.3 Basal Ganglia in Huntington 's disease 
Huntington's disease is characterized by progressive and initially selective 
striatal degeneration, causing a loss of GABAergic medium spiny neurons, specifically 
those projecting to the GPe and SNr (Weeks et al. 1997; Joel 2001). According to the 
conventional BG mode! in Hl), the selective loss of striatal projection neurons, 
specifically enkephalin containing GABAergic neurons projecting to the GPe (Tang et 
al. 2005), in the indirect pathway leads to reduced tonic inhibition of thalamocortical 
activity leading to hyperkinesia (Bhidayasiri & Truong 2004; Weeks et al. 1997). This 
suggests a deficit in inhibition which is supported by evidence that patients exhibiting 
hyperkinetic movements such as chorea have difficulty with voluntary suppression of 
these movements (Hashimoto et al. 2001). Hypokinesia of voluntary movement also 
occurs in Hl) (Bilney et al. 2003) and may be explained by the disruption of connections 
between the associative striatum and motor circuit, which are involved in the sequencing 
and selection of motor programs (Joel 2001). In this explanation, the coexistence of 
chorea and bradykinesia in early Hl) is suggested to be due to the intrusion of 
undesirable motor programs in the normal flow of motor acts, suggesting a deficient 
inhibition mechanism, and implying that chorea may be mechanically responsible for 
bradykinesia ln early stages of Hl) (Hashimoto et al. 2001; Albin et al. 1989). 
Bradykinesia ln late Hl) has been described, similar to that of Parkinson' s disease 
bradykinesia, as a deficit in the direct pathway, this would result in a mechanically 
isolated bradykinesia not resulting from chorea, but a mechanism of it's own. (Fig 3) 
Another interpretation of the model has been presented by Mink (2003) theorizes that 
cortical motor pattern generators are "gated in" and "gated out" by selective facilitation 
and sUITound inhibition, and a disruption, or random temporal patterning of this gating 
may be the cause of involuntary movement, specifically chorea in Huntington's disease. 
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a) Bradykinesia in HD b) Chorea in HD 
Striatum 
1 GPi/S;~" 
Thalamus 
Dopamine 
Excitatory Dopamine 
/inhibitory inhibitory 
-.Excitatory --.Excitatory 
GlutamateGlutamate 
-.Inhibitory ~ Inhibitory 
GABAGABA 
Figure 3. BG in Huntington 's Disease. Thick arrows highlight increased activity from 
normal and dotted arrows marked decreased activity. A) One theory of bradykinesia in 
HD is a general degeneration of both indirect and direct pathways. B) Chorea in HD is 
thought to occur due to increased inhibition of the subthalamic nucleus (STN) 
decreasing inhibition of the thalamus and increasing thalamocortical activity. (Adapted 
from Albin et al. 1989) 
2.4 Motor Symptoms 
Huntington's disease is considered a mixed movement disorder due to the 
presence of both hypokinetic and hyperkinetic symptoms, the most c1inical feature of 
which is chorea (Weeks et al. 1997; Bilney et al. 2003; Gardian & Vecsei 2004). 
Secondary motor symptoms of HD are rigidity, dystonia, akinesia, bradykinesia and 
oculomotor deficits (Hamilton et al. 2003; Gardian & Vecsei 2004; Bilney et al 2003; 
Berardelli et al. 1999). 
2.4.1 Chorea 
Chorea cornes from the Greek charos for 'chorus' meaning both dance and song 
(Higgins 2001). Chorea is c1assified as irregular, flowing, non-stereotyped movement 
that occurs at random and possesses a writhing quality (Bhidayasiri & Truong 2004; 
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Yanagisawa 1992). Chorea that is proximal and of large amplitude is referred to as 
ballistic, and irregular, forceful, writhing movements, generally in the extremities, are 
refen-ed to as athetosis (Bhidayasiri & Truong 2004). Aggravated by anxiety and stress, 
chorea begins in peripheraJ limbs and progresses to more proximal 'ballistic' movement 
(Higgins 2001; Bhidayasiri & Truong 2004). Chorea is often reduced in later stages of 
HO (Berardelli et al. 1999) and can coexist with hypokinetic features of the disease, 
such as bradykinesia (Thompson et al. 1988; Joel 2001). 
2.4.1.1 Classification ofChorea 
There are three main classifications of chorea based on the method of contraction 
and occurrence: primary or idiopathie, secondary and other sources. Primary chorea 
includes those forms idiopathie or genetic in origin, such as Huntington's disease, 
neuroacanthocytosis, Wi]son's disease, senile chorea, benign hereditary chorea and 
dentatorubral pallidoJysian atrophy (DRPLA) (Quinn et al. 1998; Bhidayasiri & Truong 
2004). Secondary chorea includes those cases caused by infectious or immunological' 
conditions such as Sydenham's chorea, drug induced chorea, immune mediated chorea 
and vascular chorea, to name only a few (Bhidayasiri & Truong 2004). Other sources of 
chorea include those due to vitamin B land B 12 deficiencies, exposure to toxins and 
paraneoplastic symptoms (Bhidayasiri & Truong 2004). Huntington's disease is the 
most common cause of chorea. 
2.4.2 Bradykinesia 
Bradykinesia is a frequent finding in HO in both early and late stages of the 
disease(Garcia-Ruiz et al. 2002). Bradykinesia can be defined as abnormal slowness of 
movement, specifically referring to a slowness in the execution of a task (van Vugt et al. 
2003). Bradykinesia is believed to be attributed to degeneration of output from the basal 
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ganglia to supplementary motor areas involved with initiation and maintenance of 
sequential movements (Berardelli et al. 1999). 
2.4.3 Rigidity 
Rigidity is defined as the inability to fully relax or completely stretch a muscle 
voluntarily. In RD abnormal EMG responses to muscle stretch and changes in SEP 
(sensory evoked potential) and long latency stretch reflexes suggest ineffective gating of 
afferent infonnation to the brain from the periphery (Mink 1996; Abbruzzese & 
Berardelli 2003). Rigidity occurs at later stages of adult-onset RD or in the akinetic rigid 
type. 
2.4.4 Dystonia 
Dystonia can be defined as abnormal co-contractions of antagonist muscle 
groups that result in twisting movements and abnormal postures (Raike et al. 2005). 
Underlying neural mechanisms of dystonia involve dysfunctional output from the basal 
ganglia and cerebellum (Raike et al. 2005). 
2.4.5 Akinesia 
Akinesia is defined as slowness of movement, referring specifically to slowed 
reaction or initiation of movement (van Vugt et al. 2003). Akinetic/rigid is a fonu of 
Huntington's also known as Westphal's and is characteristic of early/juvenile onset and 
later stages of the disease in nonual adult progression. Akinesia is thought to result from 
general damage and decrease of striatal projections in the BG. 
2.4.6 Oculomotor Deficits 
Oculomotor deficits In RD include delayed initiation of voluntary saccades, 
reduced number of correct saccades and reduced saccadic velocity (Blekher et al. 2004). 
Abnormalities of saccades may be accounted for by the extensive loss of striatal 
projection to SNr that plays a major role in controlling saccadic eye movement (Reiner 
et al. 1988). These deficits may contribute to the visual inattention and visuospatial 
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deficits exhibited in HO (Weeks et al. 1997; Kim et al. 2004; Boulet et al. 2005; 
Hamilton et al. 2003). 
2.4.7 Possible Neural Mechanisms 
The hypokinetic features of HO, rigidity and akinesia, are associated with the 
loss of striatal neurons projecting to both the GPe and GPi (Albin et al. 1990). 
Bradykinesia in the early stages of HD is suggested to be the result of under activity of 
the indirect pathway and the inappropriate tennination of muscle acti vitY (Joel 2001), 
due to the fact that the direct pathway appears to be preserved early in the disease. 
However, this assumes it is bradykinesia, the slowness of movement, and not 
bradyphrenia, sJowness of thought, which is inhibiting RD patient pelformance, 
although the latter is more likely the cause. Bradykinesia in the later stages of HO may 
be due to a similar mechanism as bradykinesia seen in Parkinson 's disease, resulting 
from under activity of the direct pathway (Joel 2001). There seems to be a dynamic shift 
in the influence of the direct vs. the indirect pathway on motor symptoms as the disease 
progresses. In PET studies bradykinesia shows no correlation to loss of either D 1 or D2 
receptor binding, which suggests overall decreases not selective degeneration are the 
cause of bradyk.inesia in HD (Turjanski et al. 1995). The hyperkinetic, involuntary 
characteristics of HO chorea suggest a disruption in the indirect pathway in the basal 
ganglia motor loop (Weeks et al. 1997; Bhidayasiri & Truong 2004). Using the 
conventional BG model, selective loss of striatal projection neurons in the indirect 
pathway would lead to reduced inhibition of the GPe, reducing inhibition of the 
thalamus resulting in hyperkinetic movement (Weeks et al. 1997, Reiner et al. 1988). 
Notably, a PET study ofDl!D2 receptor binding in HO found a reduction in both Dl!D2 
receptors in a patient exhibiting chorea only, which wou Id refute the theory of selective 
striatal degeneration as the cause of choreic movements (Turjanski et al. 1995). 
Abnormal motor cortical excitability in HD has been raised as a possible mechanism for 
choreic movements (Abbruzzese et al. 1997; Brusa et al. 2005), although recent 
evidence has challenged those findings (Priori et al. 2000; Hanajima et al. 1999) and 
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controversy has resulted as to what factors and methodological issues may be at the 
roots of such contrary findings (Abbruzzese et al. 2000). A study looking at GPi firing 
rates found no significant difference between hypokinetic Parkinson's patients and 
hyperkinetic HO patients, although the pattern of firing was different (Tang et al. 2005). 
The high firing rates in HO may be attributed to the presence of bradykinesia (Tang et 
al. 2005). The reported coexistence of bradykinesia with chorea in HO suggests there is 
a more complicated answer to the motor symptoms of this disease, possibly a 
malfunction in the motor program selection which is expressed in HO patients difficulty 
in planning and sequencing action (Kim et al. 2004; Boulet et al. 2005). Kanazawa 
(1989) proposed three mechanisms for choreic movements in HO: massive neuronal 
loss, receptor hypersensi ti vitYand post-synaptic component loss. 
2.4.7.1 Massive neuronalloss 
First, choreic movements may be the result of the massive loss of GABAergic 
inhibitory neurons in the striatum. This would induce disinhibition of the nigra 
dopaminergic neurons and causes activation of these neurons and choreic movement. 
The drawback to this proposai is that loss of GABA in the substantia nigra does not 
always correlate with generation of choreic movement (Kanazawa 1989; Tang et al. 
2005). 
2.4.7.2 Receptor Hypersensitivity 
The second possible neural mechanism underlying choreic movements is that 
there are hypersensitive dopaminergic receptors in the striatum that are causing 
hyperkinetic movement. Receptor hyper-sensitivity, specifically at the DI receptors, 
may be due to huntingtin protein induced toxicity or a compensatory mechanism for 
decreased dopamenergic input (Spektor et al. 2002). However it is generally accepted 
that dopaminergic receptors are decreased in HO and post-synaptic components are 
more influential in HO (Spektor et al. 2002: Turjanski et al. 1995). 
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2.4.7.3 Post- synaptic component loss 
The third possible mechanism is that a massive loss of striatal neurons causes a 
loss of post-synaptic components of dopamenergic termi nais that then acts to change 
existing spared striatal dopamenergic terminais. Ginovart and colleagues (1997) found a 
decrease in the density of post-synaptic dopamine receptor in the striatum in HD along 
with decreased binding to dopamine transpor1er that may suggest malfunctioning in the 
production, processing and transport of dopamine transporter, which plays an essential 
role in regulating dopamenergic neurotransmission. Both pre and post-synaptic markers 
of dopa transmission have been implicated in cognitive performance in HD (Backman & 
Farde 2001). 
2.5 Psychiatrie Symptoms 
Psychiatric symptoms are a key element in the triad of features distinguishing 
HD, the others involving motor and cognitive impairment (Paulsen et al. 2001). HD 
patients exhibit a variety of psychiatric symptoms, preceding the onset of motor 
symptoms in up to 31 % of cases (Lawrence et al. 1998; Snowden et al. 2002; Naarding 
et al. 2001; Seneca et al. 2004)! predating motor manifestations by up to a decade 
(Paulsen et al. 2001). This pre-clinical presentation of symptoms has been the target of 
observation and research in an attempt to slow the progression of the disease by 
attacking the first signs of impairment (Paulsen et al 2001). 
HD patients can express a wide array of psychiatric abnormalities including 
dysphoria, agitation, irritability, apathy and anxiety, with 3-6% of cases exhibiting 
schizophrenic like psychosis (Naarding et al. 2001; Paulsen et al. 2001). Dementia in 
HD is classified as subcortical (Weeks et al. 1997; Naarding et al. 2001). Psychotic 
symptoms have been observed earlier in disease progression, decreasing as cognitive 
impairment becomes more prominent (Leroi & Muchalon 1998). 
Treatment of psychiatric symptoms can be complicated, especially due to 
adverse side effects of medications that include motor abnormalities such as 
parkinsonism. Depression in HD can be treated similarly to major depression in non-HD 
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patients, although sensitivity to sedation and anti-cholinergic induced cognitive decline 
should be monitored (Leroi & Michalon 1998). Management of aggressive symptoms, 
ranging form iITitability to intermittent explosive disorder should focus on underlying 
cause of behavior, neuroleptics and antidepressants have been found effecti ve in 
therapeutic treatment (Mendez 1994;Leroi & Michalon 1998). 
Changes in sexuality, expressed through inappropriate behaviour and hypoactive 
sexual desire, have been reported in lID and may be related to underlying 
neurotransmitter deficits (Lerbi & Michalon 1998). No studies have systematically 
examined the management of sexual changes in lID (Leroi & Michalon 1998). Sleep 
disorders have been reported in HO with varying severity, Weigand and colleagues 
(1991) found decreased sleep efficiency, decreased slow wave sleep and prolonged sleep 
latency in HO, while others found minimal to no differences between lID patients and 
controis. 
Once agam, as with motor symptoms, the measurement tools and patient 
selection criteria have made it increasingly difficult to compare between studies. 
Medication remains a factor, as therapies prescribed for motor symptoms may cause or 
aggravate psychiatrie abnormalities in HO. 
2.6 Treatments 
There IS no CUITent therapy that is able to delay or prevent the onset of 
Huntington's disease (Bhidayasiri & Truong 2004) and therefore treatment IS 
symptomatic (Bilney et al. 2003). Physiotherapy, occupational therapy and speech 
pathology address motor impairments and limitations experienced by patients with lID 
(Bilney et al. 2003), while an increasing number of drug trials attack the neurological 
process of the disease (Qin et al. 2005). Researchers have examined the effects of the 
following agents on lID motor symptoms: anti-dopamenergic, NMDA antagonists, 
GABA agonists, DOPA Agonists, Nootropics, antioxidants and neuroprotective agents 
(Bonelli et al. 2004). Only anti-dopamenergic agents showed majority positive results, 
specifically tetrabenazine and fluphenazine (Bonelli et al. 2004). 
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Treatment of chorea in HD is difficult due to the severity of side effects 
experienced with drugs prescribed to manipulate movement in neurodegenerative 
disorders; for example the aggravation of psychiatric systems and negative effect on 
voluntary movement. Therefore, drug treatments are suggested only when chorea is 
debilitating (Bhidayasiri & Truong 2004; Bonelli et al. 2004). Initial recommendations 
for the treatment of chorea in HD involve discontinuation of medication that may have 
involuntary movement as a side effect. There are a wide variety of anti-choreic agents on 
the market, including neuroleptics that block central dopamine receptors as weil as 
dopamine depleting agents such as tetrabenazine, although these options come with 
serious side effects and only minimal evidence of symptomatic relief (Bonelli et al. 
2004; Bruneau et al. 2002). 
2.6.1 Anti-dopamenergic agents 
Anti-dopamenergic agents such as clozapine and fluphenazine are also classified 
as anti-psychotics and act to competitively block dopamine and seratonin receptors, 
although side effects associated with the use of anti-psychotics include dystonia and 
pseudo-parkinsonism (Brenner 2004). Recently tetrabenazine, an anti-dopaminergic 
agent initially designed for use as an anti-psychotic, has been found to decrease chorea 
in HD patients in a randomised control study (Huntington Study Group 2006). 
2.6.2 NMDA Antagonists 
Amantadine is an example of an NMDA receptor antagonist used in the 
treatment of HD (Qin et al. 2005). The degeneration in HD is thought to be due in part 
to sensitisation of NMDA receptors on residual striatal neurons (Qin et al. 2005). An 
antiviral drug originally used for the treatment of influenza, when used in Parkinson's 
disease, amantadine works by releasing dopamine from nigrostriatal neurons (Brenner 
2004). 
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2.6.3 GA8A Agonists 
GABA agonists are used to treat movement disorders because of their intense 
sedative properties (Soares et al. 2004), although there has been tittle success with their 
use in HO (Bonelli et al. 2004). GABA-ergic drugs act to enhance the activity of the 
inhibitory neurotransmitter GABA in the brain. GABA-ergic drugs act on the 
metabolism or its reuptake into neurones of glia, as weil as mediating the synaptic 
release of GABA (Meldrum 1982). 
2.6.4 DOPA Agonists 
DOPA agonists, or dopamine receptor agonists, directIy activate dopamine 
receptors in the striatum, specifically D2 receptors Ieading to inhibition of the indirect 
pathway (Brenner 2004). 
2.6.5 Nootropics 
Nootropics, such as piracetam, are considered 'cognition enhancing' agents, used 
in the treatment of various dementias, although poor predictive ability in animal trials 
have kept them from general acceptance (Gualtieri et al. 2002). Piracetam has 
antithrombotic and neuroprotective properties, it alters the physical properties of plasma 
membrane, increasing its fluidity and protecting against hypoxia, increasing red cell 
deformability and normalizing aggregation of hyperactive platelets (Winnicka et al. 
2005). 
2.6.6 Antioxidants 
Neurodegeneration in HO is associated with oxidative stress that is manifested 
by lipid peroxidation, protein oxidation and other markers (Butterfieid et al. 2002). 
Antioxidants agents are used to combat the oxidati ve stress that qccurs 10 
neurodegenerative disease, by sJowing progression and limiting the amount of neuronal 
ceIl Ioss (Mossmann & Behl 2002). Agents such as CoEnzyme QlO has been shown to 
protect against striatal lesions in HO mice, and is especially effective in the 
mitochondria, as the enzyme is a co-factor in the electron transport gene (BeaI 2002). 
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2.6.7 Neuroprotective Agents 
Neuroprotective agents such as Lamotrigine, also used as an anti-epileptic, 
blocks sodium channels and interferes with neuronal membrane conduction and the 
release of neurotransmitters such as glutamate (Brenner 2004). Estrogen, a natural 
neuroprotective agent, has been synthesized and found effective in cytoprotection and 
mitoprotection, and has implications for treatment in HO (Simpkins et al. 2005). 
2.6.8 Surgery 
Deep brain stimulation (DBS) and striatal transplantation surgery have been 
examined in the treatment of chorea in HO (Hebb et al. 2006; Moro et al. 2004; Hauser 
et al. 2002; Furtado et al. 2005; Lee et al. 2005). Evidence from rat models (Lee et al. 
2005) has shown functional recovery with administration of human stem cells, although 
c1inical testing in humans shows conflicting evidence, with no benefit from 
transplantation in 7 HO patients (Furtado et al. 2005). 
3. RATIONALE 
Treatment for chorea may have a deleterious effect on motor performance in 
patients with RD. For instance, sorne parkinsonism may be induced by the dopamine 
depleting agents used in treatment of chorea, resulting in increased motor impairment 
due to bradykinesia. The wealth of research examining the motor abnormality in HO 
have focused on tasks requiring timing and or accuracy, with very few studies 
exammmg or quantifying the chorea or it's effect on voluntary movement. Many 
patients participating in the following studies were on anti-choreic drugs at the time of 
testing, altering the natural effect of the involuntary movement and causing or 
aggravating hypokinetic features of movement due to the sedating effects of medication. 
The folJowing is a brief critical review of studies examining motor dysfunction in RD. 
Reilmann and colleagues (2001) used grip force as a measure of progression of RD in 
ten patients over a three-year period. The task involved precision grip and lifting of an 
instrument with two force torque sensors measuring grip and load at the thumb and 
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index finger. Participants were instructed to lift the object to a specified lOcm height and 
hold for 6 seconds. übject weight was manipulated with 10 consecutive trials at each 
weight, and order of trials randomized across patients. Results showed more variabiJity 
, 
in the follow-up period, with more variabiJity in grip force with lighter compared to 
heavier object weights. Chorea was reflected in position and orientation changes in 
object location during the static phase of the task. Variation in these movements was 
found between subjects but measures did not change during follow-up testing, the only 
measure of motor function that changes over time was rigidity, as measured by the 
U1IDRS. Increased variability over time was attributed to presence of chorea. The 
conclusion made in this study was that grip force is a useful tool in measuring 
progression of motor impairment in lID (Reilmann et al. 2001). There are several issues 
to be raised concerning this study. The first is that chorea is a phenomenon of whole 
body involuntary movement, classifying chorea as a displacement of the thumb and 
index finger during a six second task is an inaccurate measure of the influence of chorea 
on voluntary movement. Second there were multiple components to the task, precision 
grasp, lift to a specifie height, maintenance of position at that height of 6 seconds. 
Patients with lID are shown to have difficulty in sequencing movement (Agostino et 
a1.1992) and sub-movement cueing (Curra et al. 2000) which may be due to a slowness 
in initiation of movement (akinesia), slowness of thought (bradyphrenia) or slowness in 
execution or inability to generate adequate force to complete the task (bradykinesia). 
The third complication in this study lies in the fact that ail patients were on multiple 
medications, ail of which changed from the initial to the follow-up data collection, 
possibly complicating results by influencing the variability recorded in the follow-up 
period. The task is sequenced and goal directed which can complicate performance in 
lID patients by adding a cognitive component, not providing a clear picture of motor 
behavior in lID. 
Flexion and extension at the finger and elbow have also been used to measure 
motor behaviour in lID (Hefter et al. 1987; Verbessem et al. 2002). Hefter (1987) used 
self-paced isometric contraction and rapid alternating forefinger movements. 
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Hyperkinesic and voluntary contractions were compared in patients exhibiting clear 
hyperkinesias, using EMG activity. HO patients exhibited prolonged times for self­
paced contractions as weil as prolonged time to peak force. In the rapid alternating 
finger movement HO patients also exhibited slowed and more irregular movement, in 
comparison to controls. The majority of hyperkinetic contractions were found to be 
slower than voluntary contractions of a similar amplitude. Controversial points in this 
study include the fact that hyperkinesias were recorded in only one area, i.e. distal upper 
limbs, and once again ail subjects were heavily medicated. Therefore is it difficult to 
isolate the source of the slowness and variability found in their performance. AIso, the 
signal-to-noise ratio (i.e. the amplitude of the intended movement versus the chorea) was 
low, probably limiting the motor impairment to a mechanical one. Verbessem and 
colleagues (2002) used unimanual and bimanual voluntary movement involving flexion 
and extension at the elbow to test motor performance in male patients with lID. 
Unimanual tasks were performed at maximal speed, while bimanual movements were 
performed in-phase and anti-phase at different cycling frequencies. Results showed that 
subjects with HO required more time to complete one movement cycle, and had 
increased variability in measures of range and cycle duration when compared to 
controls. Speed of cycling and accuracy were correlated with disease duration. Another 
aspect of the study that is problematic, is the nature of the movement itself, unimanual 
and bimanual movements involved flexion-extension at the elbow which is a multi­
phase movement. Performance on this task could be influenced by three different 
symptoms, akinesia, bradyphrenia and bradykinesia, therefore we are no closer to 
understanding why HO patients appear to be slower then controls, a piece of information 
integral to the management of motor symptoms in lID. 
Reaction time has been a widely used measure of motor disability in HO 
patients, as weil as many other neurodegenerative conditions. Van Vugt et al. (2003, 
2004) utilized simple reaction time paradigms of response to negative stimuli and button 
pressing to determine the cause of slowness in lID. In the response to painful stimuli it 
was hypothesized that motor slowness in lID resulted From failure in activation of 
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agonist muscles and inhibition of unwanted antagonist activity. Results showed that in 
BD patients there was impaired antagonist inhibition prior to and during voluntary 
agonist contraction, and this was strongly correlated with delayed motor initiation, 
akinesia, and slow movement execution, bradykinesia (van Vugt et al. 2003), supporting 
the initial hypothesis. Another study by van Vugt (2004) looked at a buuon-pressing task 
as a measure of reaction time. Results showed that BD patients required more time for 
movement initiation and execution, displaying akinesia and bradykinesia, respecti vely. 
Botb these impairments were present in early stages of the disease and became 
progressively worse with disease progression. These studies improved on previous 
research by isolating the various sources of slowness in movement in an attempt to 
determine at what stage in movement BD patients are impaired. Jahanashi and 
colleagues (1993) looked at reaction time in choreic BD, Parkinson's and cerebellar 
disease. Results showed that patients with BD had significantly longer simple reaction 
times than patients with PD, performance improved with auditory cueing but patients 
with BD were still slower than patients with PD. Patients with BD also exhibited slower 
movement time than the PD group, an indication of the presence of bradykinesia. 
Whether these delays were induced by motor bradykinesia, or by bradyphrenia remains 
to be determined. It is interesting to note that mean age in the PD group was 
significantly greater than that of the BD group, so age was not a factor in performance of 
the simple reaction time test. One interesting note in this study is the fact that only one 
of the seven RD patients was medicated, providing evidence for the coexistence of 
chorea and bradykinesia, although chorea was not recorded during testing, it was 
measured with a subjective clinical scale prior to participation. 
Kim and colleagues (2004) used fMRI to examine the performance of a seriai 
reactio~ time task in patients with BD. The task consisted of an asterisk appearing on a 
screen in one of four boxes each associated with one of four buttons, patients were 
required to push the button of the box in which the asterisk appeared. An implicit 
leaming condition was created with trials following the same 12 item sequence 6 trials 
in a row. The purpose was to evaluate the nature and degree of functional changes in the 
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brain in the earliest stages of BD. Reaction time in the BD patients was longer then 
control s, and BD patients showed a lack of implicit leaming, a deficit consistent with 
cognitive impairment reported in BD (Kim et al. 2004). Striatal activation was highly 
variable in the BD group, suggesting early functional [oss, this data is consistent with 
previously demonstrated early atrophy in these same structures in HO. 
Carella and colleagues (2003) investigated the possibility that bradykinesia ln 
HO is task dependent. They investigated the influence of visual control on the ability of 
HO patients to complete a tracing task. Patients exhibited increased movement time and 
peak velocity in the visual control condition compared to controls, with an increase in 
movement time and decrease in peak and mean velocity in the blindfolded condition as 
compared to their own visual control values. Error scores did not differ significantly 
between HO group and control in the visual control task. Investigators suggest that the 
increased time spent in the deceleration phase may have been a compensatory method in 
response to irregular movements in HO patients. In the blindfolded condition the HO 
group exhibited significantly more variability and error. There was a lack of correlation 
between chorea scores and kinematic variables, leading investigators to conclude that 
chorea was not the source of irregular movement causing error in the task. These 
findings suggest that abnormalities of motor control are present in HD when movement 
accuracy, and not velocity, is required. 
Lemay et al. (2005) also examined BD subjects' ability to trace material with 
and without sensory manipulation, in this case patients received direct or indirect 
(through a monitor) visual feedback. Patients showed larger and more frequent 
deviations from the object to be traced when receiving indirect visual feedback. There 
were also significant group differences in velocity with patients exhibiting slower 
movement than controls, especially slower movement toward the circle, then away from 
il. Un-medicated patients were analysed separately and compared to medicated HO and 
there were no significant differences found. The results of this study imply that error 
feedback is not impaired in HD in situations with direct visual feedback, although 
sensory manipulation, such as that of indirect feedback elicits dysfunctional 
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performance. Investigators concluded that this dysfunction in indirect visual feedback 
may be due to the inefficient use of error feedback, not a fundamental problem in error 
feedback control (Lemay et al. 2005). 
Boulet and colleagues (2005) recorded aiming movements toward peripheral 
targets in HO to determine the effect of transformed visual feedback on movement 
control. Subjects were required to move a pen From a central point to a fixed peripheral 
target with indirect visual feedback on a monitor. Patients with !-ID showed significantly 
lower average speeds that controIs, aithough there was no significant difference in peak 
velocity. Patients with HO showed less precision than controls when one and both 
horizontal and vertical axis were inverted. The data suggests that the deficit in on-line 
feedback control is related to the attention demands of the task, and results From 
problems with executive control. 
Peg insertion has been used as a measure of motor performance in treated and 
untreated HD patients, controls and !-ID gene carriers (Saft et al. 2003). Participants 
were required to transfer 25 pegs to 25 holes in a computer based contact board as 
quickly as possible. The peg insertions score did not differ between !-ID groups and 
controls, although elapsed intervals between groups were significantly different. 
Differences were found between HO gene carriers and diagnosed patients with HO. 
Motor symptoms were quantified using a subjective clinical scale prior to testing and no 
mention was made of involuntary movements during the insertion task. Investigators 
admit that the task is restricted to movement of the upper limbs and therefore is unable 
to incorporate issues of whole body involuntary movement. Once again this task has 
multiple stages that may pose cognitive and mechanical sequencing difficulty for 
patients with HO. 
Timed motor tests, such as the CAPIT test used in Parkinson's disease, have 
been used to assess motor function in HO (Garcia-Ruiz et al. 2002). Tests included 
pronation-supination, finger dexterity, movement in between two points and a walking 
task. HO patients were slower than controls, with deterioration in performance at follow 
up. This study concluded that bradykinesia was the cause of this slowness and a 
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significant factor in motor impairment in BD. This conclusion is controversial due ta the 
fact that the majority of participants were being medicated for motor symptoms that rnay 
have lead to the slowness in task execution, therefore casting doubt on the origin of 
bradykinesia in these patients. 
Comparis"ün between studies is made difficult by the fact that there was no single 
method of movement quantification used, many studies selectively omÜ patients deerned 
'too choreic', and many tasks involve complex sequencing of movement and cognitive 
processes which are known to be impaired in BD patients (Curra et al. 2000; Agostino et 
al. 1992; Brandt et al. 2005). 
The coexistence of hypokinetic (bradykinesia) and hyperkinetic (choreic) 
movement abnormalities provides significant difficulty in isolating the source of 
dysfunction during movement. Bradykinesia has been recorded in BD patients of the 
akinetic rigid type, as well as those exhibiting only chorea, especially in those with 
severe chorea (Thompson et al. 1988). Clinical studies in BD indicated that difficulties 
with voluntary movement becorne more pronounced as chorea subsides (Thompson et 
al. 1988; van Vugt et al. 2004). Aggravation of bradykinesia has been associated with a 
decrease in chorea, and decrease in chorea related to a worsening of reaction time (van 
Vugt et al. 2004). This suggests that involuntary movements may not be the only, or 
even the most influential source of motor disability in HD (Thompson et al. 1988). 
Therefore the first general aim of this study will be to detelmine the mutual influence of 
chorea and voluntary movement in patients with HO. 
To date only one study has systematically quantified tri-dimensional movernent 
patterns in conditions of disordered movement. Ghassemi and colleagues (2006) 
quantified whole body involuntary movement in patients with Parkinson's disease, with 
and without dyskinesias, during a rapid altemating movement (RAM) task. In the RAM 
task, dyskinesias appeared to play a positive role in performance, and results implied 
that a reasonable assumption for this was the presence of cortical over activation 
associated with dyskinesias counteracting the reduction of thalamocortical acti vation 
associated with bradykinesia (Ghassemi et al. 2006). The same assumptions may be 
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applicable to the coexisting presence of bradykinesia and chorea in HD, as the 
bradykinesia in both PD and HD share similar characteristics during simple and complex 
movements (Thompson et al 1988). Simultaneous quantification of chorea and 
bradykinesia is critical for isolating the effect of each symptom on voluntary movement 
and evaluating the efficacy of phannacological therapies in HD. 
The issue of motor slowness in HD is addressed in the second general aim of this 
study, which is to determine if bradykinesia coexists with chorea in early 00, and if so 
what is the nature of ifs interaction with hyperkinetic features of the disease, e.g. 
chorea, as weil as ifs influence on motor performance. Two theories have been 
proposed to explain bradykinesia in early and late HD, suggesting an indirect and direct 
pathway malfunction, respectively. In order to illuminate which of these model theories 
may be correct the influence of chorea and bradykinesia on movement must be isolated. 
The current gold standard evaluation method of disease severity and progression 
in HI> is the Unified Huntington's Disease Rating Scale (UHDRS) (Huntington Study 
Group 1996; Hurelbrink et al. 2005). Other clinical measures, such as the Behaviour 
Observation Scale Huntington (BOSH) are also used to deterrnine psychiatric and motor 
abnorrnalities in patients with HI> (Timman et al. 2005). Clinical rating scales, while 
beneficial, are not able to detect sub-clinical changes as weB as sorne components of 
voluntary movement (Beuter et al. 2004). Clinical measures focus on simple tasks that 
fail to incorporate whole body activity during testing. An objective measure capable of 
capturing whole body involuntary movement in HI> is needed to assess the progress of 
the disease and help shed light on the neuro-mechanisms underlying the relationship 
between voluntary and involuntary movement in neurodegenerative diseases (Hurelbrink 
et al. 2005). A quantitative measure capable of recording abnorrnal movement is integral 
for the evaluation of new therapeutic treatments and surgical interventions (Beuter et al. 
2004), by distinguishing hypo and hyperkinetic features, their isolated and combined 
effect on voluntary movement. 
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4. HYPOTHESES 
4.1 Hypothesis 1 
Chorea is aggravated by stress (Bhidayasiri & Truong 2004) and has been observed to 
increase during movement (Mink 1996). Based on these oQservations we hypothesize 
that chorea will increase during the completion of voluntary movement tasks. 
4.2 Hypothesis II 
Bradykinesia is an accepted feature of both akinetic rigid and choreic forms of HD 
(Thompson et al. 1988: Garcia-Ruiz et al. 2002). What is not known, however, is 
whether chorea is mechanically responsible for the bradykinesia when both symptoms 
are present. Here, we hypothesize that during a RAM task, the chorea will not be 
directly responsible for bradykinesia when both symptoms are present. 
5. METHODOLOGY 
5.1 Subjects 
5.1.1 Participants 
This study included two subject groups, one comprised of diagnosed adult-onset 
Huntington's disease patients, and the other comprised of age/gender-matched controls. 
Cohen's method for power calculation was used to determine number of subjects 
required. Based on whole body involuntary movement values of a similar disease 
population, Parkinson's disease dyskinetic (Ghassemi et al. 2006), a minimum of 2 
subjects were needed for comparison of whole body involuntary movement. For the 
bradykinetic measures such as range and velocity, a miriimum of 14 subjects were 
required for comparison, as calculated by at-test with Welch's correction of degrees of 
freedom for unequal variances. 
5.1.2 Recruitment 
Participants were recruited from the London Health Science Movement 
Disorders Chnic. Ali participants were referred to the study by the neurologist Dr. M. 
log. 
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5.1.3 Inclusion/Exclusion Criteria 
AlI participants completed a UHDRS with a certified nurse to establish the 
presence of chorea and severity of motor and psychiatrie symptoms. Early stage choreic 
RD patients, diagnosed with adult onset RD, with Iittle to no psychiatrie disturbance 
were included in the study. Age matched controls were free of any neurologie or motor 
disturbances. Individuals with advanced or juvenile onset Huntington's disease were not 
included in this study. Individuals expressing bradykinesia/akinesia as the prominent 
motor symptom or severe psychiatrie symptoms were not eligible for participation. Ali 
participants were able to stand, walk or sit without the use of assistive devices. 
Individuals with metal implants (i.e. joint stabilizing plates or pins) were not included in 
the study due to the possibility of metallic interference with the testing apparatus. 
Age/gender matched controls were not considered if they suffer from any psychiatrie 
conditions or motor impairment. Ali medications being taken by patients were 
documented. 
S.l.4IRB Concerns 
Ali participants read and signed an infonned consent document detailing the 
procedures, risks and benefits of participation in this study. Participants were assigned a 
subject number, and ail documents containing personal information were stored in a 
locked cabinet accessible to the principal and co-investigators exclusively. Participants 
were able to abstain from participation at anytime without consequence. There was no 
monetary gain to participating in this study although compensation was arranged for 
travel and parking costs. 
5.2 Independent Variables 
This study involved the comparison of whole body involuntary movement and 
motor performance between two groups in two conditions. 
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The two groups included one comprised of patients with adult onset 
Huntington's disease and the other, a control group, made up of healthy age/gender 
matched participants. 
There were two experimental conditions in this study, activity and rest. During 
the active task participants were asked to participate in a motor activity while both their 
performance in that activity, as weIl as their whole body involuntary movement was 
recorded. During the rest period participants abstained from voluntary motor tasks. 
5.3 Dependent Variables 
The two measurements of interest in this study were whole body involuntary 
movement and performance on a rapid altemating movement (RAM) task. Whole body 
involuntary movement is the sum of movement in alilimbs, and is examined in terms of 
displacement in space. Performance of a voluntary task, rapid altemating pronation­
supination cycles, provides a measure of motor performance. Variables of interest within 
performance of the RAM task include range, velocity and irregularity. Range is a 
measure of the maximal excursion achieved during pronation-supination cycling. 
Velocity is a measure of the maximal instantaneous velocity achieved from peak to peak 
during a pronation-supination cycle. Irregularity is a measure of the variability in RAM 
amplitude. 
5.4 Data Analysis 
5.4.1 WBIM 
The time series provided by each sensor was divided into 7s epochs for analysis. 
The mean position for x, y and z was subtracted from the actual position to provide a 
displacement time series around a neutral position for each epoch. The RMS values for 
each x, y, z time series are squared, the mean of the three values caJculated and the root 
taken, to attain the three dimensional vectorial amplitude for each sensor. Values for 
each epoch are averaged; the sum of ail the mean vectorial amplitudes over aIl sensors 
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was then calculated to determine whole body involuntary movement. Values for sensors 
located on the performing arm were then compared to those of controls. The mean 
control value was subtracted from the values calculated for patients with HD and the 
remaining displacement in those sensors was treated as chorea. Therefore a value for 
WBIM was calculated with ail other sensors on the body and the chorea value for the 
performing arm, as determined by subtracting the mean movement associated with 
performance of the task. WBIM was also analysed topographically to determine if 
chorea in a patient is localized to either the upper/lower body or rightlleft side. 
5.4.2 RAM 
An automated algorithm was used to identify each peak and trough of the 
pronation-supination cycle. Three characteristics were calculated range, velocity and 
irregularity. Range is the mean angular displacement over a complete pronation­
supination cycle in degrees. Velocity, maximal instantaneous velocity from peak to 
peak, was calculated in degrees per second over a complete pronation-supination cycle. 
RAM cycle amplitude irregularity was calculated by normalizing the pronation­
supination time series (mean=O, SD=l), applying a low pass (1Hz) filter and obtaining 
the standard deviation of the resulting linear enveJope. A higher score reflected greater 
variability in RAM amplitude, therefore a more 'irregular' performance. The first 7s of 
the pronation-supination cycling was analysed for RAM performance as fatigue may 
become a problem, and this time period has been successful in prior work with similar 
populations (Ghassemi et al. 2006). 
5.5 Procedure 
Participants were asked to arrive at the lab at the appointed time, in comfortab1e' 
clothing. Participants were met at the main doors of the facility and escorted to the lab 
by the investigator. Participants were seated and given a copy of the letter of informed 
consent to read and sign, and any questions regarding procedure and participation were 
addressed at this point. The letter of informed consent was available in both French and 
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English, with investigators available to address questions in either language to ensure 
complete comprehension of participation. 
Once consent has been given participants will be assigned a subject number and 
asked to detail anthropometric data (i.e. height and weight) and CUITent prescription 
medication regimens. 
Pmticipants were asked to move into the testing area where a lightweight shirt 
will be placed over existing clothing. An investigator then palpated the location of each 
of the 15 sensors and attached the sensors using adjustable Velcro bands. Investigators 
were gender matched to participants for palpation and placement of sensors. Sensors 
were placed at the following locations: head, thorax, sacrum, right/left scapula, right/left 
upper arrn, right/left forearm, rightJleft hand, right/left shank and right/left foot. 
5.5.1 Data Quantification 
5.5.1.1 Whole body involuntary movement (WB1M) 
To quantify whole body involuntary movement 10 3 dimensions an 
electromagnetic measurement system with 6 degrees of freedom, the Flock of Birds 
magnetic motion tracker system (lnnovative Sports Training, Chicago, IL), was used. 
The magnetic tracker contains an extended range transmitter that permits accurate 
recording within a 12ft radius. A custom shirt, shoes and gloves are used to fix 15 
sensors adjacent to the joint axes of limbs under consideration. Each sensor provides 
displacement (x,y,z) and orientation (pitch, roll, yaw) of each limb segment. To facilitate 
testing a 3x4x6 foot area was calibrated, using an antropometer and square foot tiles to 
record 72 points, one point every O.304m (l ft) in ail three axis, defining sensor position 
in respect to the location of the transmitter coi!. The calibrated space had an accuracy of 
approximately O.005m. Each sensor has a sampling rate of 100Hz. 
5.5.1.2 Motor Performance 
Motor performance was quantified through the use of a rapid altemating 
movement (RAM) task, requiring pronation-supination cycling at maximal voluntary 
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speed and excursIOn. RAM was recorded simultaneously with WBIM usmg forearm 
rotational sensors. Two handballs were attached to the end of a lightweight wooden 
dowel, the other end of which was attached to a potentiometer, to detect rotational 
movements during pronation-supination, with a resolution of 0.3 degrees. The analog 
output from the potentiometer, sampled at 100Hz, was digitized and stored for analysis. 
5.6 Experimental Procedure 
Once participants are connected to ail sensors, they were asked to step onto the 
testing platform where a calibration recording was taken. During this recording 
participants were asked to stand upright with their arms at their sides, in anatomical 
position. Participants were then asked to stand with arms out in front for a period of 60 
seconds. Participants were seated and asked to hold the foam handballs, with arms bent 
at the elbows, approximately 3 inches, 120 degrees from their sides. Participants were 
instructed to maintain this position, at 'rest' for 20 seconds. They were then instructed, 
for a period of ten seconds, to perform pronation-supination of the dominant hand as fast 
and as complete a rotation as possible. Participants were asked to refrain from any other 
voluntary movement at this time, without restraining any involuntary movements that 
may occur. The non-dominant hand remained stationary during the RAM task. After ten 
seconds the participant was then asked to return to the rest state, both hands stationary, 
holding onto foam handballs, for another 20 seconds 'rest' recording. Three trials were 
recorded. Once the experimental procedure is completed, participants were debriefed 
and escorted out of the facility. 
5.7 Statistical Analysis 
A two-way analysis of variance (ANGYA) was used to determine the existence 
of group by condition interactions, with repeated measure for condition, for WBIM and 
amplitude of the opposite hand pre and during performance. Post hoc analysis was done 
to indicate which group comparisons yield significance. The Student Newman-Keuls 
method was used to test multiple comparisons because it utilizes a per contrast type 1 
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error rate whieh is less eonservative and affords greater power than the Tukey method 
(Glass & Hopkins 1970). A one-way ANOVA was used to determine statistieal 
signifieance of RAM performance variables, sueh as range, duration, veloeity and 
irregularity. A one-way ANOVA was also used to analyse WBIM by quadrant (i.e. 
upper/lower body, right/left side) to detennine if ehorea is topographie. 
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ABSTRACT 
Our goal was to deterrnine whether bradykinesia is present in choreic adult-onset 
Huntington's disease (BD) patients, and determine the impact of chorea on their 
voluntary movements. We recorded whole-body invoJuntary movements (WBIM) and 
voluntary motor acts simultaneously, using a magnetic tracker system, in fifteen choreic 
BD patients and fifteen healthy age-, gender-matched control subjects. Participants were 
asked to perform two distinct tasks; a rapid alternating movement (RAM) task, yielding 
measures of bradykinesia, and a manual-tracking (MT) task yielding a measure of 
chorea intrusion during accurate movements. Results show that patients with BD 
presented with deviations from the target that hindered their ability to match the target 
velocity during the MT task. Furtherrnore, error in performance was correlated with the 
amplitude of whole-body chorea (Rho = 0.67), illustrating the deleterious effect of 
chorea during accurate movements. However, patients with choreic BD presented with 
significantly higher RAM range and velocity than matched controls, therefore ruling out 
the idea that bradykinesia is a systematic feature of BD, even when chorea is 
predominant. The present results imply that patients may have benefited From an intact 
direct pathway ("select ON" pathway in the focused attention model of basal ganglia 
function) that allowed them to supersede any dysfunctions associated with the 
progressive alteration of the "control function" (striatal-globus pallidus-subthalamic) 
pathway responsible for generating the chorea. Finally, the present results suggest that 
patients with adult-onset BD having chorea would greatly benefit From improved 
treatments aiming at reducing their invoJuntary movements while maintaining proper 
motor function. Key Words: whole-body involuntary movements, chorea, basal ganglia, 
Huntington,kinetic 
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1. INTRODUCTION 
Huntington's disease (HD) is usuaJly considered a mixed movement disorder due 
to the presence of both hypokinetic and hyperkinetic symptoms, the most significant 
clinical feature of which is chorea (Weeks et al. 1997; BiJney et al 2003; Gardien & 
Vecsei 2004). There is ample evidence to suggest that the chorea itself negatively affects 
motor function, specifically accuracy (Bilney et al. 2003; Phillips et al 1996), reaction 
time (vanVugt et al. 2003; vanVugt et al. 2004; Jahanshahi et al. 1993; Kim et al 2004), 
sequencing and sub-movement cueing (Agostino et al. 1992; Curra et al. 2000), timed 
motor tests (Garcia-Ruiz et al. 2002) and gait regulation (Bilney et aJ.200S). Although 
there is extensive variability in motor symptom expression, the clinical features of 
typical adult onset HD are characterized by a progression from hyperkinetic to 
hypokinetic movements (Berardelli et al. 1999). Then, motor symptoms of RD may 
include rigidity, dystonia, akinesia and bradykinesia (Thompson et al. 1988; Berardelli 
et al. 1999; Bilney et al 2003; Hamilton et al. 2003; Gardien & Vecsei 2004). 
Aggravation of bradykinesia has been associated with a decrease in chorea, which in 
tum is related to a worsening of reaction time (vanVugt et al 2004). However, the time 
course of the appearance of bradykinetic features is still debated, especially since 
clinical and laboratory observations suggest that the two symptoms may coexist in both 
early and late stages of HD (Thompson et al. 1988; Joel 2001; Hasimoto et al. 2001; 
Kim et al 2004). Interestingly, past basal ganglia models suggest that bradykinetic and 
choreic features are the result of opposite neural disturbances (Albin et al. 1989; 
Alexander et al. 1986). More recently, Mink (2003) has suggested that chorea would be 
the result of impaired inhibition of competing motor pattern generators, and the presence 
of bradykinesia would be the result of the superposition of desired and undesired motor 
pattern generators. If this is indeed true, bradykinesia may simply be a result of 
biomechanical effect due to low signal-to-noise ratio, where the signal is the intended 
movement and the noise represents the involuntary movements. It then becomes 
important to make a distinction between "core" bradykinesia, which is the consequence 
of improper activation of cOl1ical structures by the basal ganglia-thalamo-cortical output, 
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as seen ln Parkinson's disease, and bradykinesia that is caused by mechanical 
disturbances, such as the intrusion of involuntary movements. Since the main treatment 
modality for chorea is to deplete dopamine wîth the potential side effect of drug-induced 
parkinsonism (Bonelli et al. 2004), determining whether "core" bradykinesia is a 
symptom of early HO, or simply the consequence of a low signal-to-noise ratio as 
described above, is imperative to assess whether accepted treatment may actually 
worsen an already existing and important feature of HD. Accordingly, the goals of the 
present study were: to isolate the impact of chorea on motor performance in patients 
with HD and determine whether "core" bradykinesia is being co-expressed with chorea 
during performance. In order to achieve this goal, whole-body involuntary movements 
(WBIM) were simultaneously quantified during two distinct mator tasks; a manual­
tracking (MT) task that allowed for the quantification of choreic intrusions during 
ace urate movements, and a rapid altemating movement (RAM) task that provided a 
measure of bradykinesia. 
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2. RESULTS 
Table 2. Subject Characteristics 
Subject Agel Onset UHDRS Disease Inilial/general Meds 
# Gender Motor duration symplOins 
HD03 56/f March 33 3 Whole body chorea (iow Seroquel 25mg, effexor XR 75 mg, 
2003 amplilude, continuous). premarin 0.3 mg. progesterone 100 
(42 RAM normal mg, ditropan XL 5mg 
repeals) 
HD04 33/f Early 7 6 Chorea in exlremilies and Multivilamin 
2000 face, ram (evidence of 
chorealmild bradykinesia) 
HDOS 61/f 1994 10 Chorea, RAM mildly Zyprexa 2.5mg & % mg, 
impaired Temazepam 30mg. Bupropion SR 
150mg, Crestor 10mg 
HD06 54/f 2004 2 Mild-mod chorea, chorea Alivan 1 tablet, Tylenol #2, 
(43 of eyes. hands, lrunk & Meloxicam 15mg, Sertraline 
repeats) longue, RAM normal tablet 
I-[D07 36/m 2001 (43 5 SWled with twilching, Olanzapine 2.5 mg 
repeats) now choreic, RAM normal 
lID09 61/f Jan 2000 6 Started with Chorea in Imovane 7.5mg 
lower limbs, now 
generalized chorea, RAM 
abnormal in upper and 
lower 
"DOlO 50/f 2001 5 Gencralized chorea in Salmon oil, cenlrum omega 3, 
lrunk, limbs and legs Citalopram, I3esacoydyl, serroquel 
HDOll 62/f 1995 II Tremor since age of 30, Estrogen 0.9mg, Inderal LA 60mg, 
with anxiety and Novo gabapentin 300mg. 
depression, now choreic, Paroxeline 20mg, Codeine Contin 
RAM impaired 10 right 150mg, Clonazepam 0.5mg, 
upper limb Seroquel 200mg, Ibuprofen 400mg 
I-[DOI2 58/f April 5 Moderale generalized Aricept 5 mg. Oxybalynin 5mg, 
2001 chorea, RAM normal Larazepam, Omega 3 
HD013 63/m 2001 5 Generalized chorea. RAM Niloman J 2.5mg (letrabenazine), 
(43 abnormal wilh intrusion of celexa 20mg, L-thyroxin 
repeals) choreic in upper and lower 
limbs 
HDOl4 52/f 2001 17 5 Effexor 150mg, Clonazepam 
O.5mg, Estace, Glucomine (for 
artluitis). CoQIO 
HDOIS 64/m (42 53 2 Muscle rigidily ail 4 Iimbs, Quelrapine 200mg, Minazapine 45 
repeals) RAM impaired, chorea, mgh.s, Glyburide 2.5mg, 
initially dystonia upper righl Melformin 500mg, ocusate NA 
misdiagno 100mg, Ritazopine 
sed wilh 
Tourette's 
2004 
HDOl6 60/f 2004 (-41 2 Body and face chorea Indocid loomg, Eslrogen, 
repeats) Amitriptyline 50mg, Losec 20mg, 
Ativan, Elhyl EPA study 
HDOl9 79/f 2001 44 5 Ram slow wilh dyslonic Hydrochlorolhiazide 12.5mg, 
posturing[R], chorea Bisopiolo 7.5mg, Atorvastalin 
10mg, Ramipril 10mg, 
Nitrofurantoin 100mg, Alendronate 
HD20 50/m 1990 16 Chorea, no rigidity or Cogenlin 2mgx3, Olanzapine 
tremor IOmgx3, Salicylate 800mgx4, 
Haldol, Seroquel 150mgx2, Ferrous 
Flimerale, Clomipramine 50mgx2, 
Lactlliose 30mlx2, tylenoi 325mg 
Mean ± S6.9±12.3 S.6± 3.5 
SD 
Controls SS.2±13.8 
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FIGURE 4 illustrates the changes of WBIM amplitude during the rest and active 
conditions of MT and RAM. ANGVA reveals a group effect for WBIM during MT (F = 
17.111, P < 0.05) and RAM (F = 39.790, p < 0.05) confirming the presence of 
significant chorea at rest and during voluntary movements in the HO group. RAM 
movements generated a condition effect that was presént in both groups (F =10.530, p < 
0.05), but not during MT, which suggests that the increase of WBIM amplitude with 
voluntary movement is related to the velocity of the performed motor act. 
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Figure 4. Whole Body Movement (WBM) at rest and during activity. WBIM for manual 
tracking in displacement during MT (top) and RAM in the rest (gray) and active 
conditions. Amplitude was higher for the choreic HO group, confirming the presence of 
chorea in aU conditions. The amplitude of WBIM increased significantly during 
mOvement in both groups during voluntary movement, but significantly more during 
RAM. While the increased WBIM in the contrais could be qualified as motor overflow, 
the increase of WBIM in HO patients represents an increase of chorea. *significant 
difference within group at p < 0.05. **significant difference between groups at p < 0.05. 
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FIGURE S illustrates the amount of error (performance minus target) present 
during MT. In displacement, the difference did not reach the threshold for statistical 
significance (t=2S0, p=0.481), despite a c1ear trend towards more deviation from the 
target. The HO group exhibited high variability in elTor as well as WBIM amplitude, 
therefore, a correlation was done to determine if a relationship existed between these 
variables. Results indicate that indeed patients with higher WBIM presented with 
increased deviations from target (Rho=0.67, p<O.OS). Error in velocity (difference 
between the target velocity and performance velocity) was significantly higher for the 
HO group (t=340, p <O.OS), suggestive of a difficulty in matching the target velocity 
during the different phases of movement. 
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Figure S. MT Performance. Manual tracking performance is evaluated using error in 
performance. Although the Error in displacement (top) did not reach significance, 
patients demonstrated an increased difficulty in following the target. When examining 
their ability to match the target velocity (bottom) patients with choreic HO demonstrated 
significant error. This error was highly correlated with the level of chorea (Rho = 0.67). 
*significant difference between groups at p < 0.05. 
FIGURE 6 illustrates the RAM performance for RANGE, VELOCITY 
and IRREGULARITY. Patients with HO had significantly higher RANGE (t=4.398, 
p<O.OS) and VELOCITY (t=3.072, p<O.OS) than control subjects, suggestive of 
hypermetria. Although there was a trend towards a more irregular quality of 
performance in the HO group, differences did not reach significance (t=1.996, p>O.OS). 
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Figure 6. RAM Performance. Despite receiving similar instructions, patients 
with choreic lID presented with hypermetria, as they significantly had higher RANGE 
(top), and VELOCITY (middle) than age-gender matched controls. Since the velocity 
generated by subjects may be related to the range of movement, we also present results 
(bottom) from a subset group (six HD patients and their controls) who could be matched 
for equal RANGE. In that case, the VELOCITY generated by patients was equat to that 
of their matched controls, confirming that patients with choreic HD were able to develop 
fast movements. *significant difference between groups at p < 0.05. 
FIGURE 7 shows example of MT performance and RAM performance from one 
patient with lID who had c1ear choreic intrusions in their MT performance, but had a 
slightly better performance then the control subject during RAM. 
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Figure 7. Perfonnance traces. Examining the perfolmance of HO subjects compared to 
controls on a trial-by-trial basis reveals clear qualitative differences in performance 
signais. This example illustrates the typical motor performance, during one trial, of a 
patient with relatively high levels of chorea. The intrusion of choreic movement is 
readily visible during the MT task (4a). However, that same patient is able to perform 
the RAM task with greater amplitude and velocity than its counterpart in the control 
group (4b). While the "quantity" of movement is good, the "quality" is less discernable; 
the RAM movements present with more irregularity than the control subject. 
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3. DISCUSSION 
Chorea 
Patients had significantly greater WBIM compared to controls, confinning the 
presence of chorea. Beyond this confinnation, the effect of voluntary motor activity on 
amplitude of WBlM in patients with chorea is well demonstrated. Patients and controls 
both exhibited increased WBIM amplitude during motor activity, especially during 
RAM, with the BD group providing the most dramatic example of this trend. While the 
increased WBIM in the control group could be characterized as motor overflow, the 
increased WBIM in the BD group is the result of increased chorea. These results are 
similar to those of dyskinetic PD patients, where increased dyskinesias were observed 
during voluntary motor acts (Ghassemi et al. 2006; Lemieux et al. 2007). This may 
imply that both PD and BD hyperkinetic symptoms are sensitive to increased cortical 
facilitation brought about by neural activity related to voluntary movements. 
MT 
Patients with BD expressed a significantly greater amount of error in velocity 
during the MT task compared to controls. There was a direct correlation between the 
magnitude of chorea and performance error, in both displacement and velocity. We 
found no correlation between disease duration and age with perfonnance variables. This 
suggests a predominant influence of chorea on manual tracking in patients with BD, and 
the greater the chorea, the greater the difficulty in completing such precision target­
oriented tasks. Differences between groups for displacement did not reach significance, 
which suggests that velocity errar differences are influenced by small deviations from 
the target which are corrected quickly, but none the less register as movement away 
from the target. It is reasonable then to suggest that the deviations from target were a 
direct cause of choreic intrusions in the motor performance. 
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RAM 
Patients with HD had RAM performance superior to that of controls, suggesting 
that patients were able to perform fast repetitive movements, despite significant 
increases in WBIM during activity. The HD group displayed a tendency for more 
irregularity of performance, which although not significant, highlights a difference in the 
quality of performance between groups. This evidence rules out the existence of "core" 
bradykinesia in patients with chorea, and suggests that bradykinesia reported in the 
literature is due to the use of tasks that had a low signal-to-noise ratio (here we imply 
that the noise is the chorea and the signal is the intended movement). For instance, 
several studies utilized tasks requiring multi-joint movements where purposeful slowing 
of movement was surely needed to compensate for choreic intrusions during precise 
motor acts (Kim et al 2004; Befter et al. 1987; Verbessem et al. 2002; Shaft et al 2003; 
Lemay et al 2005; Boulet et al 2005) Patients with HD have shown difficulty in 
sequencing multi-joint movement and sub-movement cuing (Agostino et al. 1992; Curra 
et al. 2000); this fact may facilitate the recording of mechanically-induced bradykinesia 
in patients, due to the exaggerated time-scale of each component of a multi-joint 
movement, highlighting the presence of any direct influence of chorea on pace of 
movement (vanVugt et al. 2003; vanVugt et al. 2004; Boulet et al. 2005;). Accordingly, 
slowness of performance recorded in previous studies (Jahanshahi et al. 1993; Garcia­
Ruiz et al. 2002; Verbessem et al. 2002) may have been the result of chorea. Then, to 
compensate for involuntary choreic movements, subjects may have attempted to 
"voluntarily" slow their performance in favour of accuracy. Another possibility is the 
fact that cognitive symptoms, which are well-described in HO, may have also 
contributed to bradykinesia being detected in other studies, as the complexity of the task 
used may have been higher in sorne experiments. The simple nature ofour task limited 
the influence of bradyphrenia on the performance of patients. Interestingly, results 
obtained using our device did not correlate with clinical observations that RAM were 
problematic in these patients. This probably stems from the fact that clinical RAM 
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differs greatly as it requires patients to either tap repetitively the index on the thumb, or 
tap the palm and dorsum of the hand on the knee, in an altemating fashion. Both these 
tasks possess a lower signal-to-noise ratio compared to full pronation-supination 
movements. 
IMPLICATlONS FOR CURRENT BG MODELS OF CHOREA 
Selective atrophy of the brain in RD occurs ln the globus pallidus and 
subthalamic nucleus, with the most severe effects reserved for the corpus striatum 
(Sharp & Ross 1996). In the neostriatum, the medium spiny neurons degenerate early, 
while the larger aspiny intemeurons are left intact (Albin et al. 1989; Albin et al. 1990; 
Hedreen & Folstein 1995; Reiner et al. 1988). The specific cause of chorea seems to 
correspond to an early selective loss of GABAergic neurons expressing enkephalin (D2) 
situated in the indirect pathway (Reiner et al. 1988). In HD, the degeneration of D2­
mediated striatal neurons causes a disinhibition of the lateral pallidal projections to the 
subthalamic nucleus. This causes the subthalamic nucleus to be exceedingly inhibited. 
The chorea, then, would be generated by a loss of subthalamic excitatory influence upon 
the medial pallidal neurons, yielding a decreased pallidothalamic inhibition upon 
thalamo-cortical pathways (Joel 2001). Consequently, the presence of chorea 
corresponds to a fundamental interruption of the indirect pathway, which involves the 
striatal-extemal paJlidum, subthalamic nucleus and Gpi (Crossman et al. 1988; Jackson 
& Crossman 1984; Mitchell et al. 1989). Later in the disease, a decrease of,thalamo­
cortical acti vity can be seen when bradykinesia and rigidity, rather than chorea, are the 
predominant symptoms (Weeks et al. 1997). Then, it is postulated that GABAergic 
neurons of the direct pathway may begin to die. However, it is possible that the direct 
pathway may begin to be affected in the earlier stage when chorea is present (Joel 2001). 
The fact that patients participating in the present study were able to perform fast 
movements as weil as controls may suggest an intact direct pathway. Voluntary 
movements are then facilitated by an intact direct pathway, while chorea would be 
generated by dysfunction of the indirect pathway. The present results also suggest that 
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two competing motor programs do not necessarily cause bradykinesia, as long as the 
signal-to-noise ratio is high. This is what we can observe during the RAM task. As 
soon as this ratio drops, as seen in the MT task, the undue influence of chorea becomes 
clear. The results may also suggest that an intact direct pathway (select ON pathway as 
described in the focused selection model from Mink, 1996) supersedes a dysfunctional 
"control function" (the equivalent of the indirect pathway in the Delong's model) 
pathway, since patients were able to generate fast movements. This was the case for 
patients with PD having dyskinesias where bradykinesia was detected with involuntary 
movements (Ghassemi et al. 2006). In that study, the performance was not correlated 
with either the amplitude of dyskinesias, rigidity or tremor, suggestive of the presence of 
"core" bradykinesia concomitantly with peak-dose levodopa-induced dyskinesias. 
Another interesting finding in the present study, and in the study of dyskinetic PD 
patients (Ghassemi et al. 2006; Lemieux et al. 2007) is the increased amplitude of 
involuntary movements during voluntary motor acts. This suggests that the efficacy of 
the hyperdirect pathway, or select OFF pathway (Mink 1996), is limited in these 
hyperkinetic disorders. This pathway has been linked to inhibition of motor behaviors 
(Nambu et al. 2002; Aron et al. 2006), and is proposed to be the main inhibitor of 
competing motor patterns in the focused attention model of Mink (1996). 
CLINICAL IMPLICATlONS 
The relevance of this study revolves around the clinicat costlbenefit analysis of 
clinically treating chorea in patients with lID. Prior studies have suggested the onset or 
aggravation of bradykinetic features of the disease with drug treatment for chorea 
(Bonelli et al. 2004). The present study has determined conclusively that chorea disrupts 
performance in tasks requiring accuracy, but that "core" bradykinesia is not a feature of 
lID when chorea is present. This fact strongly suggest that any bradykinesia detected 
after dopamine antagonist administration is the result of the drug effect, not simply an 
aggravation of an underiying sJowness of movement that has begun to develop 
simultaneously with the presence of chorea. It may also suggest that patients who do 
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present with severe hypokinesia or bradykinesia after dopamine antagonist 
administration may have already begun the transition from the hyperkinetic phase to the 
hypokinetic phase of the disease. Then, the medication may simply catalyze this 
transition. This hypothesis, however, remains to be confirmed. Interestingly, the patient 
base used in this study received a wide variety of drug treatments, and dosages. After 
examining subgroups of patients based on their medication regimen, no relationship was 
found between drug intake and RAM performance. Robust significance and correlation 
between variables rules out the possibility that other factors such as mild cognitive 
impairments, oculomotor deficits, or sensorimotor integration deficits influenced motor 
performance. 
Based on the fact that "core" bradykinesia is absent in patients with HO chorea, 
that chorea was mostly responsible for elTors during the MT task, and that chorea may 
have played a significant role in the bradykinesia found in other studies uti lizing low 
signal-to-noise ratio tasks, it is reasonable to suggest that chorea, when present, is 
predominantly responsible for motor dysfunctions in patients with HO, and should be at 
the centre of symptomatic treatment of early HO. 
CONCLUSIONS 
Our results unequivocally show that bradykinesia is not a systematic feature in 
BD when chorea is predominant, but that chorea is a main source of error in 
performance during accurate movements. Accordingly, patients with BD would greatly 
benefit from treatments aimed / at reducing chorea whi le maintaining proper motor 
function. In addition, this study may be t~e first to indicate a clinical validation of 
differential degeneration of the indirect vs. direct pathways and their relationship to 
chorea and bradykinesia, thereby adding to cun"ent models of basal ganglia dysfunction 
in lID. 
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4. EXPERIMENTAL PROCEDURES 
Participants 
Thirty participants, fifteen patients with HO (12 women, age: 56 ± 12) and 
fifteen age/gender matched control subjects (12 women, age: 55 ± 13) were tested. 
Patients were recruited through the London Health Sciences Movement Disorders 
Clinic. Control subjects were recruited from the general population. Each participant 
provided inforrned consent. Choreic RD patients, diagnosed with adult onset HO, with 
little to no psychiatric disturbance that may impede their understanding of the tasks were 
included in the study. Individuals expressing bradykinesialakinesia as the prominent 
motor symptom or severe psychîatric symptoms were not eligible for participation. Age­
matched controls were free of any neurologic or motor disturbances. Ali experiments 
were approved by the institutional Human Research Ethics Board. 
Quantification of Whole-Body Involuntary Movements (WBlM) 
In order to capture whole-body chorea in 3 dimensions, a 6-degrees-of-freedom 
electromagnetic measurement system, the MotionMonitor™ magnetic motion tracker 
was employed (lnnovative Sports Training, Chicago, Illinois). This methodology has 
been validated in dyskinetic patients with Parkinson's disease. Details on the apparatus 
and experimental procedures are described elsewhere (Ghassemi et al. 2006; Lemieux et 
al. 2007; Gour et al. 2007). In brief, subjects were outfitted with a custom shirt, Velcro 
bands, gloves and shoe covers onto which 15 sensors (receivers) that provided time 
series signaIs of both position (x, y, z) and orientation (pitch, yaw, roll) were attached. 
They were placed adjacent to the joint axes, such as the posterior surface of the head, the 
first thoracic vertebrae, sacral bone, superior spine of the scapulae, lateral surface of the 
forearms and upper-arms, back of the hands, as weIl as the lateral aspects of the calves 
and dorsal surface of the feet. During the calibration phase of the experiment, each 
sensor was then assigned to the Center of Mass of the limb by way of a digitization 
process. Using a stylus receiver, bony landmarks were palpated, and the centroid method 
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was used to form coordinate systems at the Center of Mass of each limb segment. Based 
on the height and weight of the subject, and using integrated anthropometric tables, an 
automated algorithm assigned a particular sensor to the Center of Mass of the Iimb on 
which it was positioned. 
Motor tasks 
Manual tracking (MT) 
Participants were seated and asked to hold, in each hand, a foam handball that 
was attached to rotational sensors. Recordings were taken in this position for 60 seconds 
to provide data for the 'rest' or inactive condition. Then, participants were asked to 
match the position of a computer generated horizontal target line (generated by 
DasyLab8.0 software, DASYTEC, National Instruments Company, Amherst NH) with a 
line they controlled via pronation-supination movement of the dominant hand only. The 
target line was presented on a large projector screen placed 1.5 meters in front of 
participants. The tip of the target line moved from left to right, at a variable velocity 
(between 0.25 to 0.75 HZ), and amplitude (20 to 120 degrees). Although the target 
displacement remained similar between trials, it was not possible for participants to 
antici pate changes of either target amplitude or velocity due to the irregular nature of its 
displacement. They were given the opportunity to practice the task prior to recording in 
order to familiarize themselves with the actions required to match the moving target. 
Three trials in the rest and active conditions were recorded. A pause of one minute was 
given between trials so that participants may rest their arms. This task was previously 
used and proven effective to detect intrusions of large involuntary movements such as 
levodopa-induced dyskinesias (Lemieux et al. 2007) or PD tremor (Duval et al. 2001; 
Duval et al. 2006) during voluntary movements. 
Rapid alternating movements (RAM) 
For the RAM task, testing included three trials of 60 seconds during which 
participants were instructed to maintain the 'rest' position described above for 20 
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seconds, arms bent at their side, holding one foam bail in each hand. Subjects were then 
instructed to perform pronation-supination of the dominant hand as fast and as complete 
a rotation as possible, for a period of ten seconds. After ten seconds the participants 
were asked to return to the rest state for the remaining 20 seconds. Three trials were 
recorded in each condition with periods of rest in between trials. RAM tasks have been 
validated by us (Duval et al 2001; Duval et al 2006a; Duval et al 2006b; Ghassemi et al 
2006) and others [Okada & Okada 1983; Beuter et al. 1999; Fimbel et al 2005] .to 
measure slowness of movement in different populations, and represent the ability of 
subjects to generate high velocity and to main tain it for several seconds. It is a natural 
movement that has little to no learning curve associated to il. Furthermore, this task is 
purely internally generated, which is known to utilize basal ganglia (Cunnington et al 
2000). In fact, activation of the putamen and globus pallidus is known to be related to 
the velocity (Cunnington et al 2000; Turner et al 1998) and amplitude of movement 
(Turner et al 2003). AIso, this task has relatively large amplitude in displacement and 
velocity, which reduces greatly the likelihood of biomechanical effect, and is simple 
enough to minimize greatly the influence of cognitive problems known in both diseases 
studied, which renders this task ideal to detect "core bradykinesia" 
Signal Analysis
 
Whole-body involuntary movements (WBIM)
 
Each sensor time seties was divided into 7-second epochs. Then, the mean 
position for x, y, and z was subtracted from the actual position of x, y and z, yielding a 
displacement time series around a neutral position for each of the epochs. We then 
squared the root mean square (RMS) values for each of the x, y and z time series, and 
calculated the mean of these three squared RMS values. Finally, we computed the root 
of this mean, thus yielding three-dimensional vectorial amplitude for each sensor. 
Values obtained from each 7-second epoch were then averaged. WBIM amplitude was 
determined by computing the sum of all these mean vectorial amplitudes over all 
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sensors. Sensors allocated to the performing limb (i.e., hand, forearm and upper arm) 
were excluded From analysis. WBIM was calculated in both displacement (meters) and 
veloci ty (mes-1). 
MT 
To quantify displacement. ERROR (in degrees) for the MT performance, the 
target line was subtracted from the subjects' performance. Then, the mean of the 
absolu te values of the remaining signal was computed. ERROR velocity was also 
calculated by subtracting target velocity From the velocity of performance, obtaining an 
ERROR value in deges- 1• The goal was to determine if differences existed between 
groups in their abi litYto match target velocity. 
RAM 
An automated algorithm was used to identify each peak and trough of the 
pronation-supination cycle. Three characteristics were then calculated: range, velocity, 
and irregularity. Range is the mean angular displacement over a complete pronation­
supination cycle in degrees. Velocity represents the maximal instantaneous velocity 
From peak to peak, and is provided in degrees per second. Irregularity is a measure of the 
variability in RAM amplitude. Only the first seven seconds of the pronation-supination 
cycles were analysed for RAM performance as fatigue may confound results (Ghassemi 
et al. 2006; Duval et al. 2006; Duval et al. 2001). 
Statistics 
To date, no studies have analysed WBIM and motor performance in patients with 
HD and controls, nor compared motor performance using the motor tasks proposed here. 
However, based on results obtained in a previous study in dyskinetic Parkinson's disease 
patients (Ghassemi et al. 2006) a minimum of 2 subjects is needed to obtain a power of 
0.80 for comparison of Wl?IM amplitude between patients and controIs. For 
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performance measures such as range and velocity, 15 subjects are required for 
comparison to obtain a power of 0.80. In order ta compare group (patients vs controls), 
condition (rest versus active), and group x condition interrelations, we used a two-way 
analysis of variance (ANOVA), with repeated measures for condition. Post hoc analysis 
(Newman-Keuls) was used to indicate which group comparisons yielded significance. 
T-tests were used to determine statistical significance between groups for each RAM 
and MT performance characteristic. Finally, we used Spearman's Rank correlations to 
ex.amine possible interactions between age, disease duration, WBIM amplitude and 
motor performance characteristics. The threshold of significance was set at p < 0.05 for 
ail aforementioned measures. 
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7. GENERAL CONCLUSION
 
We hypothesized that chorea in patients with BD would be aggravated by stress, 
I.e. increased by performing a motar task, and that chorea would not be the cause of 
bradykinesia when both symptoms are present. 
It became obvious during testing that in order to fully capture the dynamics of 
motor performance in patients with HD, the RAM task must be accompanied by one that 
isolates intrusions of chorea during movement, hence providing a measure of chorea's 
influence on motor tasks demanding accuracy. Accordingly, we also included in our 
result section the motor performance of participants during a manual-tracking (MT) task, 
which would compliment and broaden implications of performance outcomes. 
Our study illustrated that chorea indeed increases du ring voluntary movement, 
across several motor tasks, in patients with BD. The absence of bradykinesia in patients 
with BD in our study suggest that slowness of movement reported in the literature may 
be due to inappropriate signal to noise ratio of performance tasks (Agostino et al. 1992, 
Curra et al. 2000, Hefter et al. 1987, Verbessem et al. 2002), which were unable to 
distinguish between influence of chorea and bradykinesia. In fact, chorea may have been 
directly implicated in the slowness of movement, when present. Also, the effect of 
disease phase and expression cannot be ruled out as a factor in the presence of more 
hypokinetic features of BD in these previous studies. It is hard to determine what the 
source of this bradykinesia was, as previous studies have not simultaneously recorded 
chorea with performance measures. 
Our results also support previous hypotheses (see model by Penney & Young, 
Weeks et al. 1997, Reiner et al. 1988) that suggest that the direct pathway remains intact 
during the most 'choreic' phases of adult onset HD. This compliments our original 
hypothesis, illustrating that the presence of chorea in patients with BD does not cause 
bradykinesia during a motor task. 
This study has shown, through correlations between whole-body involuntary 
movements (WBIM) and error in performance in displacement and velocity, that chorea 
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is the main source of perfonnance en-or in subjects with choreic HO, and therefore, 
warrants therapeutic development and aggressi ve treatment. 
Strengths of the Present Study 
The current study is the first to simultaneously WBIM and motor performance in 
patients with HO chorea. The quantification of movement in 3-dimensions provides a 
foundation for the analysis of innumerable characteristics and qualities of who le-body 
voluntary and involuntary movements that are crucial for understanding human 
movement in health and disease. 
The measures incorporated in this study, i.e. rapid altemating movement and 
manual tracking tasks, were able to isolate, with exceptional precision, the impact of 
hypo- and hyper- kinetic features of movement in these subjects, shedding light on the 
dynamic interrelationships between voluntary and involuntary movement in RD. In 
order to full y understand and effecti vely treat symptoms of movement disorders, such as 
RD, there must be an acknowledgment of the effects of each symptom in isolation and 
interaction with one another. These measures enable the isolation and comparison of the 
effects of hypo- and hyperkinetic movement, providing a foundation on which to build a 
better model of the pathways eliciting the concomitant release of hypo-, hyperkinetic 
motor symptoms, as weIl as voluntary motor behaviours. 
Limitations of the Present Study 
Limitations of the present study include subject number, variability of subject 
characteristics and lack of clinical rating scale data. Although subject number was low, 
n=15, this number satisfied statistical requirements for the comparison of both WBIM 
measures and those of motor perfonnance on rapid altemating and tracking tasks (see 
power calculation in statistics section). In fact, this study represents one of the largest 
studies using quantitative methods to examine chorea and its impact on voluntary 
movements. 
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It became obvious during testing that our inclusion criteria were unrealistic and 
would severely limit the context and implications of our work. Therefore, we increased 
the breadth of our inclusion criteria so as to add those receiving medication and who use 
assistive devices. Subjects varied in age, disease duration and medication type/dosage. 
Despite the challenge this variability in subject characteristics may have posed, we 
recorded robust trends in performance and magnitude of WBIM that diminished the role 
any one factor may have had on findings. Surprisingly, almost ail patients showed 
similar levels of performance in both tasks, reducing greatly the variance within that 
group. 
We were unable to obtain UHDRS clinical rating data for ail subjects. However, 
keeping in mind that the purpose of this study was not to correlate UIIDRS scores with 
performance on our motor tasks, in addition to the fact that WBIM values clearly show 
that HO subjects tested were choreic, this limitation did not compromise the findings of 
this study in any way. 
Qualitative analysis of recordings in both patients with HO and control subjects 
raised the issue of movement strategies (i.e. upper and lower arm involvement in the 
completion of pronation-supination activity) utilized during motor tasks. It became 
apparent that the variability in strategy, and therefore amount of movement in the 
perfonning arm, was significant. For instance, sorne subjects had their elbow moving 
more than others during the RAM or MT. Therefore, to remove the influence of 
'movement strategy' on whole-body displacement during recording, we removed the 
performing arm sensors (those located on the hand, lower and upper arm of the 
perfonning ann) from calculations of whole-body movement. Removal of these 
performing arm sensors did not impact significance between groups on any of the 
variables compared. 
Future Implications and Research 
In future work continuing in the analysis of motor performance in RAM and MT 
tasks, adding grip force quantification would allow for another dimension of movement 
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interaction. Grip force recorded simultaneously with WBIM will provide insight into the 
dynamics of performance, which grip force alone, is unable to provide. This would 
synchronize muscle activation with behavioural output and allow compatison of 
activation levels and points of error or accuracy in performance. 
Analysis of patterns in WBIM, in a topographical, as weil as mathematical sense 
would continue to shed light on the charactetistics of involuntary and voluntary 
movement. AIso, compating the present data with that of other disorders with similar 
clinical manifestations could greatly increase our understanding of subtle similarities 
and difference in types of involuntary and voluntary movements in basal ganglia 
. disorders. 
Future research and therapy should focus on the efficient tailoring of medication 
to reduce chorea while maintaining optimal motor performance, i.e. avoiding sedative 
effects of overmedication. Manipulating dosage and medication schedules would enable 
peak performance of anti-choreic agents, enhancing efficiency on scales of both 
economy and quality of life. Analysis of the relationship between pathophysiological 
variables, such as CAG repeats and volumetric fluctuations, would enable a more 
comprehensive understanding of how structural and behavioural changes in the time­
course of disease progression may alter the final out-put of motor organization and 
pathways. This information is not only fundamental in understanding Huntington's 
disease and other basal ganglia disorders, but will enhance our understanding of these 
basic pathways in healthy conditions as weil. Quantification of WBJM, simultaneously 
with motor performance, is an integral stepping-stone in the comprehensive analysis of 
the cause and progression of movement disorders. 
Continued research which incorporates simultaneous 3-dimensional capture of 
whole-body movement is, we believe, pivotai to advancement and discovery in basal 
ganglia disorders. 
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Votre participation se limitera à une seule visite, d'une durée d'environ trois 
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Votre dossier sera codé de façon à ce qu'il demeure confidentiel et gardé dans une 
filière sous clé, où seuls les responsables du projet y auront accès. Les données 
nooùnales (nom, adresse ou toute autre indication) seront conservées pendant 5 ans et 
détruites ou anonymisées à la fin de ce délai. Pendant ces 5 ans, les données 
nooùnales seront conservées dans un fichier à part des données scientifiques. En cas 
de présentation des résultats de cette recherche ou de publication dans des revues 
spécialisées, rien ne pourra pennettre de vous identifier ou de vous retracer. 
Une exception sera faite dans les cas où les données de recherche devraient être 
révisées par un comité de déontologie, le comité d'éthique de la recherche ou par les 
organismes qui subventionnent cette recherche. Les membres de ces comités sont 
tenus de respecter les exigences de confidentialité. En outre, un tribunal peut, par 
ordonnance, autoriser un tiers à consulter les données de recherche vous concernant. 
SIGNATURES, précédées des noms écrits en lettres moulées: 
Je déclare avoir lu et pris connaissance du projet, de la nature et de l'ampleur de 
ma participation, ainsi que des risques auxquels je m'expose tels qu'exprimés dans le 
présent formulaire. 
Nom du participant Signature du participant 
Fait à le _ 
Je, soussignéee) , certifie: 
a) avoir expliqué au signataire intéressé les termes du présent formulaire;
 
b) avoir répondu aux questions qu'il m'a posées à cet égard;
 
c) lui avoir clairement indiqué qu'il reste à tout moment libre de mettre un terme à sa
 
participation au projet de recherche décrit ci-dessus. » 
Nom du chercheur ou de son représentant Signature du chercheur ou de son représentant 
Fait à , le _ 
18 septembre 2006. Certificat éthique #2006-0604 4 
ACC~SAUXCHERCHEURS: 
Le responsable du projet, Dr Christian Duval, chercheur et professeur, peut être 
rejoint aux deux endroits suivants: 
Centre de recherche de l'Institut universitaire de gériatrie de Montréal 
4565, chemin Queen Mary, Montréal, Québec, H3W 1W5. 
Tél. : (514) 340-3540. 
Département de Kinanthropologie 
Université du Québec à Montréal 
Case postale 8888, succursale Centre-Ville 
Montréal, Québec, H3C 3P8 
Tél. : (514) 987-3000 poste 4440 
EN CAS DE PLAINTE 
Pour tout problème éthique concernant les conditions dans lesquelles se déroule 
votre participation à ce projet, vous pouvez, après en avoir discuté avec la personne 
responsable du projet si possible, faire part de vos préoccupations à la responsable des 
plaintes de l'Institut universitaire de, gériatrie de Montréal à l'adresse suivante: 
Madame Denyse Marier, Commissaire locale à la qualité des services Institut 
universitaire de gériatrie de Montréal, 4565, chemin Queen Mary, Montréal, Québec 
H3vV 1W5, téléphone (514) 340-3517. 
INFORMATIüN SUR LA SURVEILLANCE ÉTHIQUE 
Le comité d'éthique de la recherche de l'Institut universitaire de gériatrie de Montréal 
a approuvé ce projet de recherche et s'assure du respect des règles éthiques durant tout 
le déroulement de la recherche. Pour toute information, vous pouvez rejoindre le 
secrétariat du comité d'éthique de la recherche au (514) 340-1424 poste 3250. 
18 septembre 2006, Certificat éthique #2006-0604 5 
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ANNEX-7 CONSENT ENGLISH
 
Université du Québec à Montréal 
Study of voluntary and involuntary movements in Park.inson's disease and Huntington's disease 
" \ /./ --~-~ Z;;::irTUT UNIVERSITAIRE DE GÉRIATRIE DE MONTRÉAL UQÀM 
Univmité du Ouéhec àMontréalCHUM 
Consent Form to Participate in Research 
A. Introduction 
1 being asked to partlclpate ln a research study 
involuntary movements in Parkinson's disease or Huntington's disease. 
It is important that 1 read and understand the nature of this study, duration, number of 
vlstts, benefits and risks. 1 should discuss any questions that concem me with the study team. 
This research project is supervised by Christian Duval PhD, from the Department of 
Kinanthropologie at Université du Québec à Montréal. This research project is conducted in 
collaboration with Dr Michel Panisset MD, Sylvain Chouinard MD, and Dr Jean-Pierre Blanchet 
MD PhD. From the movement disorders cIinic at the Hotel-Dieu Hospital (CHUM) The 
research team also inciude Alison Fenney, a Graduate student at the Université du Québec à 
Montréal. 
B. Purpose 
Patients with either Parkinson's disease or Huntington's disease may suffer from 
involuntary movements. We intend to determine the impact of these involuntary movements on 
your daily activities. 
C. Procedures 
Approximately 14 patients with Parkinson's disease and 14 patients with Huntington's 
disease showing involuntary movements will participate in this study. In addition, ten subjects 
free of neurological disease will participate (control group). The total duration of the experiment 
is approximately 3 hours, which inciudes the receptor placement, the calibration, the 
measurements and removal of sensors. 1 was explained that if 1 am in the one of the patient 
groups, 1 will be asked to maintain my normal medication schedule. 
Then, the motor performance will be tested. 
Movement evaluation 
1 was explained that small sensors are placed on my body, using elastic bands. Then a 
cali bration of the equipment will be done. 
Université du Québec à Montréal 
Study of voluntary and involuntary movements in Parkinson's disease and Huntington's disease 
l will perform three different tasks: (a) standing with arms stretched in front of me for 60 
s, (b) l will be seated comfortably on a chair, elbows flexed to 90° For this experiment, I will be 
asked to pronate and supinate (like trying to open a door using the doorknob) as fast as possible 
for 10 s, or (c) to follow a target presented on a computer monitor for 30 s, using a bail attached 
to a angular measuring device. 
l was explained that instructions will be presented to me on a projector screen so that I 
will always know the task to be performed. During this time, the position of my body will be 
monltored using the sensors that were placed on my body. I understand that aIl of the above 
procedures are done for this research study exclusively and are not part of my usual clinical 
assessment of symptoms for Parkinson's disease or Huntington' s disease 
D. Risks of participation 
I was explained that there are no known risks associated with the devices used in the 
present experiment, except for sorne fatigue. However, I may ask questions related to the 
methodology, this at any time during the experiment. 
E. Benefits of participation 
I was explained that I will not have any immediate benefits from participating in this 
study. But, this study will greatly improve our understanding of the effect of dyskinesia on 
voluntary movements. My neurologist will have access to the results for consultation. If 1 am 
interested, l may ask for a copy of the publication that may ensue. 
I understand that I am participating in this experiment on a strictly volunteer basis and I 
am free to withdraw at any time prior to or during the experimental session, without prejudice to 
me effect on my medical care. 
l understand that aIl the information obtained during the course of this study is strictly 
cOl1fidential and will not be released to anyone, including my doctor, without my written consent 
to the researchers. However, this information may be used to advance the body of scientific 
knowledge and may therefore be published in scientific joumals where my anonymity will be 
entirely preserved. 
f. Compensation 
No monetary compensation is given to participate in the study. However, traveling expenses will 
be reimbursed. 
g. Questions 
I am entirely free to ask any question that I believe is relevant. Any question about the 
project, complaints, or comments may be addressed to any of the investigators involved in this 
research project. In addition, I am invited to ask any type of additional explanations if I have any 
Université du Québec à Monlréal 
Sludy of voluntary and involuntary movements in Parkinson's disease and Huntinglon's disease 
doubts about my willingness to participate in this research project. The coordinates of the 
researcher responsible for this study listed at the end of this consent form: 
1 understand that this research project has received approval from the UQAM's Institutional 
Ethics Committee regarding research involving human subjects. For questions regarding the 
responsibility of UQAM's researchers involved in this project, or to file any complains that 
could not be addressed directly to the researchers, 1 may communicaté with the President of the 
Ethics Committee, Dr. Joseph Josy Lévy. He can be reached at (514) 987-3000 # 4483 or 
through the secretarial office of the Ethics committee at 987-3000 # 7753, 
------------
Université du Québec à Montréal 
Study of voluntary and involuntary movements in Parkinson's disease and Huntington's disease 
1 have read the information above and discussed it with the investigator to my satisfaction. In 
addition, 1 am satisfied of the explanations that 1 have received. 1 am aware of the risks involved 
in participating in these experiments outlined in this consent form. 1 consent to be a subject in 
the research project entitled "Study of voluntary and involuntary movements in Parkinson's 
disease and Hunti ngton' s disease" 
Date: _ ____ ,2005
 
(Month) (Day)
 
Name: Signature: _ 
(Print) 
Witness:	 Signature:
-------------,---- ­(Print) 
Coordinates: 
Christian Duval, Ph.D.:	 Telephone number: (514) 987-3000 extension 4440 
E-mail: duval.christian@ugam.ca 
CIÉR at UQÀM:	 secrétariat du Comité: service de la recherche et de la création 
Université du Québec à Montréal 
C.P. 8888, succursale Centre-ville 
Montréal, QC 
H3C 3P8 
Telephone number: (514) 987-3000 extension 7753 
E-mail: src@ugam.ca 
Département de kinanthropologie:	 Université du Québec à Montréal 
Case postale 8888, succursale Centre-ville 
Montréal (Québec) Canada 
H3C 3P8 
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